US20060137697A1 - Ventricular restoration shaping apparatus and method of use - Google Patents

Ventricular restoration shaping apparatus and method of use Download PDF

Info

Publication number
US20060137697A1
US20060137697A1 US11/244,865 US24486505A US2006137697A1 US 20060137697 A1 US20060137697 A1 US 20060137697A1 US 24486505 A US24486505 A US 24486505A US 2006137697 A1 US2006137697 A1 US 2006137697A1
Authority
US
United States
Prior art keywords
left ventricle
patch
shaper
heart
shape
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/244,865
Inventor
Gregory Murphy
Suresh Reddy
Albert Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Southwest Corp
Original Assignee
Chase Medical LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060137697(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chase Medical LP filed Critical Chase Medical LP
Priority to US11/244,865 priority Critical patent/US20060137697A1/en
Publication of US20060137697A1 publication Critical patent/US20060137697A1/en
Assigned to CMI HOLDING COMPANY, INC reassignment CMI HOLDING COMPANY, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHASE MEDICAL, LP
Assigned to CAPITAL SOUTHWEST CORPORATION reassignment CAPITAL SOUTHWEST CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CMI HOLDING COMPANY, INC.
Assigned to CAPITAL SOUTHWEST CORPORATION reassignment CAPITAL SOUTHWEST CORPORATION CORRECTIVE ASSIGNMENT TO CORRECT THE RE-RECORD THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 020462 FRAME 0048. ASSIGNOR(S) HEREBY CONFIRMS THE FROM ASSIGNMENT TO SECURITY AGREEMENT. Assignors: CMI HOLDING COMPANY, INC.
Assigned to Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C. reassignment Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C. SECURITY AGREEMENT Assignors: CHASE MEDICAL, LP
Assigned to CAPITAL SOUTHWEST CORPORATION reassignment CAPITAL SOUTHWEST CORPORATION SECURITY AGREEMENT Assignors: CMI HOLDING COMPANY, INC.
Assigned to CHASE MEDICAL, LP reassignment CHASE MEDICAL, LP RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/02Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
    • A61B17/0218Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for minimally invasive surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2496Devices for determining the dimensions of the prosthetic valve to be implanted, e.g. templates, sizers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0493Protective devices for suturing, i.e. for protecting the patient's organs or the operator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42Gynaecological or obstetrical instruments or methods
    • A61B17/4241Instruments for manoeuvring or retracting the uterus, e.g. during laparoscopic surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00535Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/02Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
    • A61B2017/0237Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for heart surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A61F2/2481Devices outside the heart wall, e.g. bags, strips or bands

Definitions

  • This invention relates generally to surgical methods and apparatus for addressing cardiomyopathy, and more specifically to methods and apparatus for restoring the architecture and normal function of a mammalian heart.
  • the function of a heart in an animal is primarily to deliver life-supporting oxygenated blood to tissue throughout the body. This function is accomplished in four stages, each relating to a particular chamber of the heart. Initially deoxygenated blood is received in the right auricle of the heart. This deoxygenated blood is pumped by the right ventricle of the heart to the lungs where the blood is oxygenated. The oxygenated blood is initially received in the left auricle of the heart and ultimately pumped by the left ventricle of the heart throughout the body. It can be seen that the left ventricular chamber of the heart is of particular importance in this process as it is relied upon to pump the oxygenated blood initially through an aortic valve into and ultimately throughout the entire vascular system.
  • the amount of blood pumped from the left ventricle divided by the amount of blood available to be pumped is referred to as the ejection fraction of the heart.
  • a healthier heart has a higher ejection fraction.
  • a normal heart for example may have a total volume of one hundred milliliters and an ejection fraction of 60 percent. Under these circumstances, 60 milliliters of blood are pumped with each beat of the heart. It is this volume in the normal heart of this example that is pumped with each beat to provide nutrients including oxygen to the muscles and other tissues of the body.
  • the heart is part of the body tissue, and the heart muscle also requires oxygenated blood. Its normal function is greatly upset by clotting or closure of the coronary arteries. When the coronary arteries are blocked, an associate portion of the heart muscle becomes oxygen-starved and begins to die. This is clinically referred to as a heart attack. Ischemic cardiomyopathy typically occurs as the rest of the heart dilates in an attempt to maintain the heart's output to the body.
  • the affected myocardium dies losing its ability to contribute to the pumping action of the heart.
  • the ischemic muscle is no longer capable of contracting so it cannot contribute to either squeezing or twisting motion required to pump blood.
  • This non-contracting tissue is said to be “akinetic.”
  • the akinetic tissue which is not capable of contracting, is elastic so that blood pressure tends to develop a bulge or expansion of the chamber.
  • this muscle tissue is not only akinetic, in that it does not contribute to the pumping function, but it is in fact “dyskinetic,” in that it detracts from the pumping function. This situation is particularly detrimental as the heart loses even more of its energy due to pumping the blood to the bulge instead of through the aorta.
  • the body After a heart attack, the body seems to realize that with a reduced pumping capacity, the ejection fraction of the heart is automatically reduced. For example, the ejection fraction may drop from a normal 60 percent to 20 percent. Realizing that the body still requires the same volume of blood for oxygen and nutrition, the body causes its heart to dilate or enlarge in size so that the smaller ejection fraction pumps about the same amount of blood. As noted, a normal heart with a blood capacity of seventy milliliters and an ejection fraction of 60 percent would pump approximately 42 milliliters per beat. The body seems to appreciate that this same volume per beat can be maintained by an ejection fraction of only 30 percent if the ventricle enlarges to a capacity of 140 milliliters.
  • This increase in volume not only changes the volume of the left ventricle, but also its shape.
  • the heart becomes greatly enlarged. An enlarged heart will tend to change its architecture from the normal conical or apical shape, to a generally spherical shape.
  • ischemic cardiomyopathy is the reduction in the ejection fraction which may diminish, for example, from a normal 60 percent to only 20 percent. This results clinically in fatigue and in an inability to do stressful activities that require an increase in output of blood from the heart.
  • the output of blood by the enlarged heart at rest is kept normal, but the capacity to increase output of blood during stress (i.e., exercise, walking) is significantly reduced.
  • stress i.e., exercise, walking
  • the change in architecture has a dramatic effect on wall thickness, radius, and stress on the heart wall.
  • the twisting motion of the heart which can account for as much as one half of the pumping action, is lost.
  • congestive heart failure is a major cause of death and disability in the United States with approximately 400,000 new cases annually.
  • the exact placement of the patch has been visually determined using only a visual indication where the typically white scar tissue meets the typically red normal tissue.
  • Location of the patch has been facilitated in a further procedure where a continuous suture has been placed around the ventricular wall to define a neck for receiving the patch.
  • the neck has been formed in the white scar tissue rather than the soft viable muscle. This procedure has relied on cardioplegia methods to stop the beating of the heart and to aid in suture placement.
  • the ejection fraction has been increased, for example, from 24 percent to 42 percent.
  • the shape of the reconstructed ventricle is also important. If the left ventricle is reconstructed in a spherical shape, a twisting motion of the heart about its apex, which can account for as much as one half of the pumping action, is lost.
  • the spherical shaped reconstructed ventricle must rely almost totally on the lateral squeezing action to pump blood.
  • This lateral squeezing action is inefficient and very different from the more efficient twisting action of the heart. What is needed, therefore is a reliable method and apparatus to allow a surgeon to reconstruct the left ventricle to the appropriate shape, size and contour.
  • an improved apparatus and method for restoring the geometry of the left ventricle to counteract the effects of cardiac remodeling.
  • One embodiment of the present invention provides an apparatus and method to reconstruct an enlarged left ventricle of a human heart, using a shaper, having a size and shape substantially equal to the size and shape of an appropriate left ventricle, wherein the shaper is adapted to be temporarily placed into the enlarged left ventricle during a surgical procedure.
  • Another aspect of one embodiment comprises a ventricular patch adapted for placement into the left ventricle of a heart made from a sheet of biocompatible material, and having a plurality of markings coupled to the sheet, wherein the markings are configured in distinct patterns for post operatively evaluating movement of the patch.
  • a device is presented, comprising of a handle and a sizing template adapted to be coupled to the handle. Such components are also presented as a kit for use during ventricular restoration surgery.
  • FIG. 1 illustrates one embodiment of a process utilizing several aspects of the present invention.
  • FIG. 2 a is a side view of one embodiment of a shaping device.
  • FIG. 2 b is a side view of a balloon embodiment of a shaping device.
  • FIG. 2 c is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 d is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 e is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 f is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 g is a side view of a wire frame embodiment of a shaping device in an expanded condition.
  • FIG. 2 h is a side view of a wire frame embodiment of a shaping device in an expanded condition.
  • FIG. 2 j is a section view cut transversely through the embodiment of FIG. 2 h.
  • FIG. 3 a is a top view of one embodiment of a patch.
  • FIG. 3 b is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 c is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 d is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 e is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 4 a is a top view of one embodiment of a set of sizers.
  • FIG. 4 b is a top view of one embodiment of a handle to be used with the set of sizers illustrated in FIG. 4 a.
  • FIG. 4 c is a detailed section view illustrating a connection between the handle and a sizer.
  • FIG. 4 d is a section view of one embodiment of a sizer.
  • FIG. 4 e is a section view of one embodiment of a sizer.
  • FIG. 4 f is a section view of one embodiment of a sizer.
  • FIG. 4 g is a top view of one embodiment of a sizer made of malleable wire.
  • FIG. 4 h is a side view of the sizer illustrated in FIG. 4 g.
  • FIG. 5 a is a top view of one embodiment of a patch holder.
  • FIG. 5 b is a top view of one embodiment of a suture hook.
  • FIG. 6 is a top view of one embodiment of a kit for surgically reshaping a ventricle.
  • FIG. 7 a illustrates one embodiment of a process utilizing several aspects of the present invention.
  • FIG. 7 b is a continuation of the process illustrated in FIG. 7 a.
  • the method 100 may use the following components: a shaping device 200 ( FIG. 2 a ), a patch 300 ( FIG. 3 a ), a sizer 402 a ( FIG. 4 a ), and a suture hook 520 ( FIG. 5 ).
  • a surgeon determines the appropriate size for the patient's left ventricle based on the patient's height, weight, body surface area and other patient specific conditions. Once the patient's appropriate ventricle size has been determined, at step 104 , the surgeon can then select the appropriate volume for the shaping device 200 .
  • the surgeon opens up the chest cavity in a conventional manner.
  • An incision is cut into the myocardial wall of an enlarged heart in step 108 .
  • the surgeon may remove all or some of the non-viable tissue (i.e., the dyskinetic and akinetic areas) of the myocardium.
  • a continuous round stitch known in the art as a Fontan stitch, may then be woven into the ventricle, at step 114 .
  • the stitch produces an annular protrusion, which forms an opening.
  • the shaping device 200 may be inserted into the ventricle through this opening.
  • the musculature of the myocardium may be pulled over the shaping device to form a left ventricle having a predetermined volume, shape and contour.
  • the shaping device 200 may then be compressed and removed at step 120 .
  • the surgeon may determine the preferred location of and size of the patch 300 which may be placed in the left ventricle.
  • the patch 300 is then cut to size in step 124 and secured to the inside of the myocardium in step 126 .
  • the ventricle is closed by joining the myocardial walls over the patch.
  • the Shaping Device :
  • FIG. 2 a illustrates one embodiment of a shaping device 200 .
  • the shaping device 200 In an inflated condition, the shaping device 200 is pre-shaped to generally model the appropriate volume and shape of the left ventricle.
  • the shape of the normal heart is of particular interest as it dramatically affects the way that the blood is pumped.
  • the left ventricle which is the primary pumping chamber, is somewhat conical or apical in shape in that it is longer (long axis longest portion from aortic valve to apex) than it is wide (short axis widest portion from ventricle wall to septum) and descends from a base with a decreasing cross-sectional circumference to a point or apex.
  • the left ventricle is further defined by a lateral and posterior ventricle wall and a septum, which extends between the auricles and the ventricles.
  • the pumping of the blood from the left ventricle is accomplished by two types of motion.
  • One of these motions is a simple squeezing motion, which occurs between the lateral wall and the septum.
  • the squeezing motion occurs as a result of a thickening of the muscle fibers in the myocardium. This compresses the blood in the ventricle chamber and ejects it into the body. The thickness changes as the ventricle contracts. This is seen easily by echocardiogram and can be routinely measured.
  • the other type of motion is a twisting or writhing motion, which begins at the apex and rises toward the base.
  • the rising writhing motion occurs because the heart muscle fibers run in a circular or spiral direction around the heart. When these fibers constrict, they cause the heart to twist initially at the small area of the apex, but progressively and ultimately to the wide area of the base.
  • These squeezing and twisting motions are equally important, as they are each responsible for moving approximately one-half of the blood pumped.
  • FIG. 2 a there is shown a shaping device 200 that allows the left ventricle to be reconstructed back to a pre-enlarged operating condition.
  • the reconstructed heart can be formed closer to the size and shape of the pre-enlarged heart. Consequently, the heart performs better post operatively than with conventional methods.
  • the shaping device 200 is generally conical or “tear drop” in shape.
  • the length “L” of the shaping device 200 may vary with each patient and will typically be a function of the volume selected for the shaping device. Depending on the patient, the length “L” may be in the three to four inch range to generally match the length of the pre-enlarged left ventricle. A surgeon may select the appropriate volume for the shaping device by estimating the volume of the pre-enlarged left ventricle.
  • the appropriate volume of the pre-enlarged left ventricle for a patient may be estimated to be 50 to 70 cc per square meter of body surface area.
  • the shaping device may be of an “appropriate shape” for a patient.
  • the shaping device may be of a shape similar to the shape of the left ventricle.
  • the shaping device 200 may be a generally conical shaped object composed of portions of spherical elements having different radii.
  • a width W 1 of the shaping device 200 is approximately 0.543*L.
  • the back surface 202 of the shaping device 200 is generally shaped as a portion of a sphere, having a radius of 0.802*L.
  • a width W 2 of the shaping device 200 is approximately 0.628*L.
  • the side surfaces 204 a and 204 b are combinations of portions of spheres with different radii. Between the line A-A and the line C-C, the side surfaces 204 a and 204 b have a radius of 0.515 L.
  • a width W 3 of the shaping device 200 is 0.435*L. Between the line C-C and the line E-E, the side surfaces 204 a and 204 b have a radius of 0.945 L.
  • the shaping device 200 narrows from the line designated “E-E” through a line designated as “F-F” to a vertex 206 at point “G”. It is important to note that the above discussion is illustrative of only one embodiment of the present invention and is not meant to limit the invention to the above ratios or shapes.
  • a proximal end of the filler tube 208 may be connected to a fluid reservoir, such as a syringe 210 which may inject a pre-specified amount of fluid into the balloon 201 through the filler tube 208 .
  • a fluid reservoir such as a syringe 210 which may inject a pre-specified amount of fluid into the balloon 201 through the filler tube 208 .
  • a fluid control device such as a stopcock 212 .
  • the injection of fluid through the filler tube 208 inflates the balloon 201 to an inflated condition, as illustrated in FIG. 2 b . Once inflated, the fluid inside the shaping device may be prevented from escaping by locking the stopcock 212 . This allows the balloon 201 to stay inflated with the proper volume, shape and contour during the reconstruction procedure.
  • the fluid pressure inside the balloon 201 may also be monitored by a pressure transducer, such as a piezoelectric transducer (not shown) coupled to the filler tube 208 with a y-connection (not shown).
  • a pressure transducer such as a piezoelectric transducer (not shown) coupled to the filler tube 208 with a y-connection (not shown).
  • one lead of the y-connection would be coupled to a pressure monitor and the other lead would be coupled to the fluid source.
  • the pressure monitor could be coupled to a three way stopcock (not shown), which would monitor the pressure on the filler tube side of the three way stopcock.
  • the fluid used to fill the balloon 201 may be any one of a number of fluids, such as saline solution or distilled water.
  • a sealed balloon containing a silicone gel such as a liquid methyl silicone resin capable of being vulcanized blended with a dimethyl silicone fluid.
  • a sealed balloon would not need an external fluid reservoir, such as syringe 210 .
  • the balloon 201 may be conventionally formed on a mandrel (not shown) having dimensions corresponding to the shape, contour and size of the shaping device.
  • the mandrel can be made of metal, glass or a hardened gelatin.
  • the mandrel is dipped into a polymer solution, which leaves a thin polymer coating on the mandrel surface. After the polymer has cured, the balloon 201 is removed by peeling the thin coating off the mandrel or by flushing mandrel material out of the shaping device.
  • the shaping device of the present invention may be made out of a variety of materials in a number of configurations creating a number of embodiments.
  • the shaping device is molded from a thermoplastic polymer such as PVC or polyethylene or a similar material
  • the balloon may be “non-expandable” when inflated.
  • the balloon 201 will not significantly expand beyond the original shape.
  • several shaping devices might have volumes ranging from 100 cc to 150 cc at 10 cc increments. If a surgeon predetermines that a patient's pre-enlarged left ventricle was 128 cc., then the surgeon might select a non-expandable balloon having a volume of 130 cc. A surgeon could also request a custom non-expandable balloon with a volume specifically sized for an individual patient.
  • 2 c is a section view of an embodiment showing thickened walls of an “expandable balloon” 220 .
  • An insertion or distal end 222 of the balloon 220 has walls at a maximum thickness. From the line A-A, the wall thickness progressively decreases to a vertex 224 at point G. In some embodiments, the vertex 224 connects to the filler tube 208 .
  • the wall thickness will depend on the expansion range of the balloon. For example, for an expansion of 100 to 150 cc, the thickness of the balloon would vary from 0.01′′ at a thin end to 0.05′′ at the thick end. Thus, this size or volume of this embodiment may be controlled by controlling the amount and pressure of the fluid injected into the balloon 220 .
  • the shaping device could be a balloon within a balloon.
  • FIG. 2 e illustrates such an embodiment.
  • a balloon 250 is generally shown in FIG. 2 e .
  • the balloon 250 comprises an outer balloon 252 and an inner balloon 254 .
  • the inner balloon 254 is inflatable with a fluid, such as saline solution fluid.
  • the inner balloon 254 may be inflated through the filler tube 208 .
  • a space 256 between the inner balloon 254 and the outer balloon 252 may be pre-filled with a gel 258 , such as a silicone gel or saline solution.
  • FIG. 2 f is a section view illustrating another embodiment of a balloon 260 formed to be puncture resistant.
  • the wall 262 proximal to the vertex 206 is progressively thickened to protect the proximal side of the balloon 260 from punctures during the reconstruction procedure.
  • the wall 262 could be coupled to protective pads located around the vertex 206 to protect the balloon 260 from punctures.
  • the balloon could be made from a thick, self sealing latex rubber. Such latex compounds are well known in the industry.
  • FIG. 2 g illustrates a shaping device 280 made from a wire skeleton or frame.
  • the wire frame could be made from surgical grade stainless steel, titanium, tantalum, or nitinol, which is a commercially available nickel-titanium alloy material that has shape memory and is superelastic. Nitinol medical products are available from AMF of Reuilly, France, and Flexmedics Corp., of White Bear Lake, Minn.
  • the shaping device 280 illustrated in FIG. 2 g is in an expanded condition.
  • Running through the center of shaping device 280 is a main shaft 282 .
  • the main shaft 282 has a distal end 284 and a proximal end 286 .
  • a joint 288 At the distal end 284 is a joint 288 .
  • Coupled to the joint 288 is a series of back ribs 290 a though 290 h (only back ribs 290 a through 290 e are visible in FIG. 2 g ).
  • Back ribs 290 a through 290 h are connected to front ribs 292 a - 292 h by hinges 294 a though 294 h (only front ribs 292 a - 292 e and hinges 294 a - 294 e are visible in FIG. 2 f ).
  • the proximal end of front ribs 292 a through 292 e are connected to a collar 296 through a series of hinges (not shown) radially spaced around collar 296 .
  • the use of hinges around collar 296 encourages front ribs 292 a - 292 h to form a convex angle with respect to shaft 282 at collar 296 .
  • FIG. 2 h shows the shaping device 280 in a collapsed position.
  • back ribs 290 a - 290 h and front ribs 292 a - 292 h surround shaft 282 as illustrated in FIG. 2 j .
  • FIG. 2 j is a section view cut transversely through shaft 282 and the front ribs 292 a - 292 h .
  • a surgeon may slide collar 296 along shaft 282 towards distal end 284 . The force exerted on collar 296 will cause the ribs to buckle radially outward as illustrated in FIG. 2 g .
  • the front ribs 292 a - 292 h will bend under the applied force. Because the front ribs 292 a - 292 h are under stress, they will tend to push the collar 296 towards proximal end 286 .
  • a lock 294 prevents any desired movement towards proximal end 286 .
  • the lock 294 is spring (not shown) activated and is designed such that the collar 296 may easily slide over the lock when moving from the proximal end 286 to the distal end 288 .
  • the surgeon may collapse the shaping device 280 by pressing down on lock 294 which will allow the collar 296 to slide past the lock 294 towards the proximal end 286 .
  • a patch is often used in the ventricle reconstruction procedure.
  • a patch is made from sheet material and may be a variety of shapes, including circular, elliptical, or triangular, preferably sized and configured with a shape similar to a Fontan neck, as discussed below.
  • an elliptical patch 300 may have a length between 30 and 50 millimeters along a major axis 302 and a width along a minor axis 304 of between 20 and 30 millimeters.
  • the preferable thickness of the patch is in the range of 0.3 to 0.7 mm.
  • the water permeability is preferably less than 5 ml per cm sq. per minute at 120 mm Hg.
  • the burst strength of the patch is preferably 30 to 35 kg/cm 2 .
  • the 45° angle suture retention strength of the patch should be greater than 3 kg.
  • the sheet material for the patch 300 may be formed from a biocompatible synthetic material, for example, from polyester, Dacron (Hemoshield) manufactured by the DuPont Corporation, or polytetrafluoroethylene (Gortex).
  • the sheet material may also be autologous pericardium, or some other fixed mammalium tissue such as bovine pericardium or porcine tissue.
  • the biocompatible synthetic material patch may be collagen impregnated to assist in hemostasis, or it may be sprayed with a hemostatic sealant to achieve better and instantaneous hemostasis.
  • the patch may have markings that enable the movement and position of the patch to be post-operatively observed and analyzed under imaging systems, such as Magnetic Resonance Imaging (“MRI”), x-ray machines, fluoroscopy or other external visualization methods, for post-operative clinical evaluation. Such markings will allow identification of the patch and allow for analysis of the heart's contractility in future post-operative evaluations.
  • imaging systems such as Magnetic Resonance Imaging (“MRI”), x-ray machines, fluoroscopy or other external visualization methods
  • the markings may be radiopaque.
  • Radiopaque markings are made from material that are impenetrable to radiation such as x-rays. Radiopaque markings may be applied to the patch material in a wide variety of methods. For instance, if the patch material is from a woven fabric, then radiopaque threads could be woven into the fabric at regular intervals. Such radiopaque threads could be metal and made from alloys of gold, nitinol, platinum, or stainless steel. Radiopaque threads could also be made of a biocompatible polymeric material mixed with a metal powder, such as barium sulfate. Radiopaque markings could also be imprinted onto the fabric with radiopaque ink. Such ink is available from Creative Imprints Inc., (Norton, Mass.).
  • the markings may also be attached to the material by a variety of mechanical means such as sewing or weaving the markings into patch material or using microclips.
  • the markings such as metal threads may also be attached to the material by adhesive means, such as a bio-compatible glue.
  • bio-compatible glues are available from Bioglue, Cryolife Inc. (Kennesaw, Ga.) or Cyanoacrylate, by Loc Tite Corp.
  • the markings must be arranged in a pattern that allows post operative evaluation.
  • One such pattern is a series of equally spaced substantially parallel lines as illustrated in FIG. 3 b .
  • Another pattern is a grid of substantially parallel lines as illustrated in FIG. 3 c . The distance between these parallel lines may be in standard units, such as 1 centimeter.
  • Another pattern could be in the form of concentric circles, as illustrated in FIG. 3 d .
  • Yet, another pattern could be a series of lines radiating from a single point at, for instance, a set angle apart. Such a pattern is illustrated in FIG. 3 e.
  • FIG. 4 a there is illustrated a set of sizers 402 a - 402 d .
  • the sizers 402 a - 402 d are shaped to be the approximate size of the patch 300 ( FIG. 3 a ). Similar to the patch, the sizers 402 a - 402 d will be of various geometries, length and width combinations. For illustrative purposes, the sizers 402 a - 402 d discussed herein will be elliptical in shape. For posterior repairs to the ventricle, however, the sizers may have a general triangular shape. Referring back to FIG.
  • the handle 404 may also be made from stainless steel, plastic or any other suitable material.
  • the handle 404 includes a shaft 408 having a proximal end 410 and a distal end 412 .
  • the distal end 412 couples to the connection 406 of the sizers 402 a - 402 d .
  • the proximal end 410 is coupled to a hand grip 414 .
  • the hand grip 414 is sized to fit a human hand. Such hand grips are well known in the art. A surgeon may connect any of the sizers 402 a - 402 d to the handle 404 .
  • handle 404 with a sizer allows the surgeon to easily estimate the size of the opening to be patched by holding the sizer up to and into the opening. If the sizer is too small, another one may be selected. This process may be repeated until the surgeon feels he has a sizer of the correct shape and size. As will be explained in greater detail below, once the proper size has been determined the sizer may be placed on material and be used as a template to cut the patch 300 to the appropriate size.
  • FIG. 4 c is a section view illustrating the connection 406 between the distal end 412 of shaft 408 and the sizer 402 a .
  • the connection 406 comprises a circular opening 422 .
  • Embedded in the walls of the opening 422 and running through the opening 422 is a rod 420 .
  • the rod 420 may be made of surgical stainless steel or another appropriate rigid material.
  • the distal end 412 includes a slot 425 with angular walls forming two flanges 423 a and 423 b .
  • At the base of the slot 425 is a circular groove.
  • the circular grove runs generally parallel to the slot 425 and has an interior diameter slightly larger than the exterior diameter of rod 420 .
  • the sizers may have a cutting edge which can be used to cut the patch 300 to the appropriate shape.
  • FIG. 4 d a sizer 430 is shown connected to the handle 408 .
  • the sizer 430 may have a ridge 432 concentric to the shape of the sizer 430 .
  • the ridge 432 allows a surgeon to accurately estimate the size of the opening by placing the ridge 432 into the opening.
  • the sizer 430 may also have a circumferential flange or lip 434 around the perimeter of the sizer to assist in defining the patch size.
  • the patch will typically be slightly larger than the size of the opening.
  • the width of the lip 434 will preferably have a constant width around its circumference, typically in the range between 5 and 8 centimeters.
  • a cutting edge 434 may also be coupled to the perimeter of the lip. In operation, the surgeon may use the sizer as illustrated in FIG. 4 d to estimate the size of the opening, remove the sizer 430 from the handle 408 , turn the handle over with respect to the handle 408 , and re-attach the sizer 430 to the handle 408 . The cutting edge 434 may then be used to cut the patch material to the correct size and shape by pressing the cutting edge into the patch material.
  • a set of cutting dies could also be provided which corresponds to the set of sizers.
  • there would be a corresponding cutting die sized to be slightly larger than the sizer.
  • a surgeon Once a surgeon has determined the correct sizer, he could then select the corresponding cutting die and use the cutting die to cut the patch material to the appropriate size.
  • a set of pre-cut patches could be provided, each pre-cut patch corresponding to a particular sizer in the set of sizers. The use of pre-cut patches would eliminate the need to cut the patch material to the required shape.
  • the pre-cut patches may also have pre-printed suture lines which may be used as a guide for the surgeon when attaching the patch to the heart.
  • FIG. 4 e illustrates an embodiment of a sizer 440 having a protrusion 442 concentric to the shape of the sizer 440 .
  • the protrusion 442 may also be used to define a suture line on the patch material by pressing the protrusion 442 against the patch material causing an indentation in the patch material which the surgeon can use as a guide to suture the patch.
  • FIG. 4 f which illustrates embodiment of a sizer 450 having a slot or groove 452 concentric to the shape of the sizer.
  • the groove 452 may be used by the surgeon to define a suture line by allowing the surgeon to use a marking instrument, such as a pen, to trace the suture line on the patch material.
  • FIG. 4 g illustrates yet another embodiment of a sizer.
  • the sizer 460 may be a malleable wire 462 coupled to movable legs 464 a - 464 d ( 464 a and 464 b are visible in FIG. 4 g ).
  • the moveable legs 464 a - 464 d are coupled to a handle 466 .
  • the handle 466 includes a shaft 468 having a proximal end 470 and a distal end 472 .
  • the distal end 472 couples to the movable legs 464 a - 464 d .
  • the proximal end 470 is coupled to a hand grip 474 .
  • the hand grip 474 is similar to the handgrip 414 of FIG. 4 b .
  • 4 h is a section view of the sizer 460 cut through the movable legs 464 a - 464 d .
  • the malleable wire 462 may be manipulated by the surgeon into any appropriate shape. Additionally, because one end 466 of the malleable wire 462 is free to slide past the moveable legs 464 a and 464 d , the perimeter of the shape formed by the wire may be lengthened or shortened as desired.
  • the suture hook 520 is “L” shaped and made of stainless steel, plastic or another rigid material.
  • the suture hook 520 has a long leg 522 which may be approximately 6 inches long. Coupled to long leg 522 , is short leg 524 which may be in the range of one-eighth to one-quarter inch long.
  • the suture hook 520 is adapted to be used to pull up on the sutures in the patch 300 to secure the patch 300 to the heart.
  • kits 600 for surgically reshaping the left ventricle of the heart is illustrated in FIG. 6 .
  • the kit 600 may include any of the components discussed above, including: the balloon 201 coupled to the syringe 210 , a set of the sizers 402 a - 402 d in various shapes and sizes, a handle 404 to attach to the sizers 402 a - 402 d , material 602 for creating the patch 300 (not shown), the suture hook 520 and, the patch holder 500 (not shown).
  • the components of the kit 600 may be packaged in a sterile manner as known in the relevant art.
  • the intent of the procedure initially is to remove that portion of the wall, which is not capable of contracting.
  • Such portions include the scarred dyskinetic segments, which are easy to see visually, and may also include akinetic segments, which do not contract.
  • FIG. 7 illustrates generally a method 700 for performing and using at least one embodiment of the present invention.
  • a surgeon determines the appropriate size for the patient's left ventricle based on the patient's height, weight, body surface area and other patient specific conditions (as discussed previously in reference to FIG. 2 a ). Once the patient's appropriate ventricle size has been determined, at step 704 , the surgeon can then select the appropriate volume for the shaping device.
  • step 706 the patient's chest cavity is opened up in a conventional manner.
  • step 708 an incision is cut into the myocardial wall of the dilated heart. If the surrounding tissue is dyskinetic, it will typically be formed entirely of thin, elastic scar tissue. It is the elasticity of this scar tissue, which causes the detrimental ballooning, or bulging effects previously discussed.
  • the electrical methods might include the use of an electromyogram which detects electrical impulses from active tissue to distinguish between the akinetic and viable tissue.
  • Positron Emission Tomography (PET) scanning, Single Proton Emissions Computer Tomography and Electrical Mapping Electrophysiology are all other examples of a method to determine viable tissue from akinetic tissue with by electrical means.
  • Electrical Mapping Electrophysiology a catheter is inserted into the heart to find areas void of electrical activity.
  • the portion of the tissue in the ventricle and septal walls may be excised from the epicardium from the incision to the borderline separating akinetic tissue from viable tissue.
  • This border between akinetic and viable tissue becomes the preferred location of the patch and forms an imaginary circumferential line between the non viable areas and viable areas of the myocardium.
  • a continuous Fontan stitch may be placed in proximity to the line, along the long axis of the heart.
  • the Fontan stitch produces an annular protrusion, which forms a neck relative to the circumferential line.
  • the annular protrusion may be further defined by placing a rim support around its perimeter. This neck initially may have a round circular configuration.
  • a second Fontan stitch may be placed 90 degrees from the initial stitch along the short axis of the heart. Other stitches may be placed as needed to form the heart to the shaping device. The stitch will serve to shape the heart along the short axis of the heart if needed.
  • the size of the opening in the neck formed by the Fontan stitch will vary from patient to patient. If the patch 300 is used to close the ventricle, the surgeon should determine the size of the patch to be used (step 726 ). To determine the appropriate size of the patch, the surgeon may connect any of the sizers 402 a - 402 d to the handle 404 to measure the size of the opening, and thus, the size patch 300 that is needed to fit into the neck formed by the Fontan stitch or stitches. In step 728 , the surgeon may then construct a patch. In embodiments with different sizers, once the proper sizer has been selected, the sizer can be placed on the patch and be used as a template to cut the patch 300 to the appropriate size. Alternatively, a surgeon may select a precut patch.
  • continuous or interrupted sutures can be threaded through the rim covered annular protrusion.
  • the rim covering acts as a large continuous pledget along the perimeter.
  • the suture line can be sprayed with a hemostatic agent or an agent can be applied to achieve better and instantaneous hemostasis.
  • the operative site can be closed by joining or folding over the myocardial walls. Care should be taken not to distort the right ventricle by folding the septum wall over the ventricular wall.
  • the lateral wall can be disposed interiorly of the septum wall so a majority of the force on the patch is diverted to the lateral wall. These walls can be overlapped in close proximity to the patch in order to avoid creating any cavity between the patch and the walls.
  • the patient can be weaned off bypass usually with minimal, if any inotropic support. Decannulasation may be accomplished with conventional methods (step 736 ).
  • the human heart contains an electrical conduction system which sends electrical impulses to spark the heart muscle into regular cycles of contraction.
  • This conduction system includes a Sinoatrial node (SA node), Atrioventricular Node (AV node), and Purkinie Fibers which act as conduits for the electrical pulses.
  • SA node is located in the right atrium.
  • the electrical impulse leaves the SA node and travels to the right and left Atria, causing them to contract together. This takes 0.04 seconds.
  • the electrical impulse has now traveled to the Atrioventricular Node (AV node).
  • the electrical impulse now goes to the Bundle of His, then it divides into the Right and Left Bundle Branches where it rapidly spreads using Purkinje Fibers to the muscles of the Right and Left Ventricle, causing them to contract at the same time.
  • ventricular restoration may compromise the conduction system due to the fact that a ventricle portion has been severed or excluded, the pacing or rhythm of the impulses between the right and left ventricles of the heart may get out of synchronization after ventricular restoration.
  • This asynchronous pacing contributes to a reduced output by the left ventricle.
  • restoring or assuring synchronization would assist the reconstructed left ventricle to maximize the output of the left ventricle.
  • Synchronization may be restored or controlled by implanting a pacemaker or a Biventricular pacing device (“BVP”) before closing the chest cavity.
  • BVP Biventricular pacing device
  • a pacemaker comprises: (1) an implantable controller that sets the heart rate to the desired interval, and (2) two leads that deliver electrical impulses to specific regions of the heart (i.e., one lead is placed in the right atrium and the second lead in right ventricle) to artificially cause contractions of the ventricle at the appropriate time and synchronization.
  • BVPs have a third lead designed to conduct signals directly into the left ventricle.
  • one lead is placed in the right atrium, the second lead in right ventricle, and third lead is placed to pace the left ventricle (i.e., in a tributary of the coronary sinus in the left ventricle).
  • simultaneous electrical impulses are given to both left and right ventricles so the time delay in traveling of electrical impulse is significantly reduced which aids in restoring the normal physiology of the heart and improves the pumping action of the heart.
  • Pacemakers and biventricular pacing devices are available from Medtronic, Inc. (Minneapolis, Minn.), Guidant Corporation (Menlo Park, Calif.), and St. Jude Medical Inc. (St. Paul, Minn.).
  • the mortality associated with ventricular restoration is primarily from sudden death caused from extremely fast arrthymias.
  • the higher risk of arrthymias may be caused from the removal of a portion of the left ventricle. This risk may be prevented by implanting a defibrillator at the time of the ventricle restoration.
  • the automatic implantable cardioverter/defibrillator is commonly referred to as an AICD.
  • the AICD is a device that is similar to a pacemaker, but continuously monitors the heart rhythm. If the AICD detects an abnormally fast or slow heart rhythm, it either electrically paces the heart very fast or delivers a small electrical shock to the heart to convert the heart rhythm back to normal.
  • Some BVP devices have defibrillators built into the circuitry that controls the pacing. Implanting a bi-ventricular pacing device with defibrillator after surgical ventricular restoration will not only optimize the output of the ventricle but also prevent many sudden deaths.
  • closure of the chest cavity may be accomplished in step 740 by conventional methods.

Abstract

Apparatuses and methods are provided to reconstruct an enlarged left ventricle of a human heart, using a shaper, having a size and shape substantially equal to the size and shape of an appropriate left ventricle, wherein the shaper is adapted to be temporarily placed into the enlarged left ventricle during a surgical procedure. Another aspect of one embodiment comprises a ventricular patch adapted for placement into the left ventricle of a heart made from a sheet of biocompatible material, and having a plurality of markings coupled to the sheet, wherein the markings are configured in distinct patterns for post operatively evaluating movement of the patch. In another aspect of one embodiment, a device is presented, comprising of a handle and a sizing template adapted to be coupled to the handle. Such components are also presented as a kit for use during ventricular restoration surgery.

Description

    CROSS REFERENCE
  • This invention claims the benefit of U.S. Provisional Patent Application Ser. No. 60/272,073 filed on Feb. 28, 2001.
  • TECHNICAL FIELD
  • This invention relates generally to surgical methods and apparatus for addressing cardiomyopathy, and more specifically to methods and apparatus for restoring the architecture and normal function of a mammalian heart.
  • BACKGROUND
  • The function of a heart in an animal is primarily to deliver life-supporting oxygenated blood to tissue throughout the body. This function is accomplished in four stages, each relating to a particular chamber of the heart. Initially deoxygenated blood is received in the right auricle of the heart. This deoxygenated blood is pumped by the right ventricle of the heart to the lungs where the blood is oxygenated. The oxygenated blood is initially received in the left auricle of the heart and ultimately pumped by the left ventricle of the heart throughout the body. It can be seen that the left ventricular chamber of the heart is of particular importance in this process as it is relied upon to pump the oxygenated blood initially through an aortic valve into and ultimately throughout the entire vascular system.
  • The amount of blood pumped from the left ventricle divided by the amount of blood available to be pumped is referred to as the ejection fraction of the heart. Generally, a healthier heart has a higher ejection fraction. A normal heart, for example may have a total volume of one hundred milliliters and an ejection fraction of 60 percent. Under these circumstances, 60 milliliters of blood are pumped with each beat of the heart. It is this volume in the normal heart of this example that is pumped with each beat to provide nutrients including oxygen to the muscles and other tissues of the body.
  • The heart is part of the body tissue, and the heart muscle also requires oxygenated blood. Its normal function is greatly upset by clotting or closure of the coronary arteries. When the coronary arteries are blocked, an associate portion of the heart muscle becomes oxygen-starved and begins to die. This is clinically referred to as a heart attack. Ischemic cardiomyopathy typically occurs as the rest of the heart dilates in an attempt to maintain the heart's output to the body.
  • As the ischemia progresses through its various stages, the affected myocardium dies losing its ability to contribute to the pumping action of the heart. The ischemic muscle is no longer capable of contracting so it cannot contribute to either squeezing or twisting motion required to pump blood. This non-contracting tissue is said to be “akinetic.” In severe cases the akinetic tissue, which is not capable of contracting, is elastic so that blood pressure tends to develop a bulge or expansion of the chamber. In this situation, this muscle tissue is not only akinetic, in that it does not contribute to the pumping function, but it is in fact “dyskinetic,” in that it detracts from the pumping function. This situation is particularly detrimental as the heart loses even more of its energy due to pumping the blood to the bulge instead of through the aorta.
  • After a heart attack, the body seems to realize that with a reduced pumping capacity, the ejection fraction of the heart is automatically reduced. For example, the ejection fraction may drop from a normal 60 percent to 20 percent. Realizing that the body still requires the same volume of blood for oxygen and nutrition, the body causes its heart to dilate or enlarge in size so that the smaller ejection fraction pumps about the same amount of blood. As noted, a normal heart with a blood capacity of seventy milliliters and an ejection fraction of 60 percent would pump approximately 42 milliliters per beat. The body seems to appreciate that this same volume per beat can be maintained by an ejection fraction of only 30 percent if the ventricle enlarges to a capacity of 140 milliliters. This increase in volume, commonly referred to as “remodeling”, not only changes the volume of the left ventricle, but also its shape. The heart becomes greatly enlarged. An enlarged heart will tend to change its architecture from the normal conical or apical shape, to a generally spherical shape.
  • On the level of the muscle fibers, it has been noted that enlargement or dilation of the heart causes the fibers to reorient themselves so that they are directed away from the inner heart chamber containing the blood. As a consequence, the fibers are poorly oriented to accomplish even the squeezing action, as the lines of force become less perpendicular to the heart wall. This change in fiber orientation occurs as the heart dilates and moves from its normal elliptical shape to its dilated spherical shape. The spherical shape further reduces pumping efficiency since the fibers which normally encircle the apex to facilitate writhing are changed to a more flattened formation as a result of these spherical configurations. The resulting orientation of these fibers produces lines of force, which are also directed laterally of the ventricle chamber. Thus, the dilation and resulting spherical configuration greatly reduces contraction efficiency.
  • Perhaps the most notable symptom of ischemic cardiomyopathy is the reduction in the ejection fraction which may diminish, for example, from a normal 60 percent to only 20 percent. This results clinically in fatigue and in an inability to do stressful activities that require an increase in output of blood from the heart. The output of blood by the enlarged heart at rest is kept normal, but the capacity to increase output of blood during stress (i.e., exercise, walking) is significantly reduced. Of course, the change in architecture has a dramatic effect on wall thickness, radius, and stress on the heart wall. In particular, it will be noted that absent the normal conical shape, the twisting motion of the heart, which can account for as much as one half of the pumping action, is lost. As a consequence, the more spherical architecture must rely almost totally on the lateral squeezing action to pump blood. This lateral squeezing action is inefficient and very different from the more efficient twisting action of the heart. The change in architecture of the heart will also typically change the structure and ability of the mitral valve to perform its function in the pumping process. Valvular insufficiency can also occur due to dilatation.
  • Although the dilated heart may be capable of sustaining life, it is significantly stressed and rapidly approaches a stage where it can no longer pump blood effectively. In this stage, commonly referred to as congestive heart failure, the heart becomes distended and is generally incapable of pumping blood returning from the lungs. This further results in lung congestion and fatigue. Congestive heart failure is a major cause of death and disability in the United States with approximately 400,000 new cases annually.
  • Following coronary occlusion, successful acute reprefusion by thrombolysis, (clot dissolution) percutaneous angioplasty, or urgent surgery can decrease early mortality by reducing arrhythmias and cardiogenic shock. It is also known that addressing ischemic cardiomyopathy in the acute phase, for example with reperfusion, may salvage the epicardial surface. Although the myocardium may be rendered akinetic, at least it is not dyskinetic. Post-infarction surgical re-vascularation can be directed at remote viable muscle to reduce ischemia. However, it does not address the anatomical consequences of the akinetic region of the heart that is scarred. Despite these techniques for monitoring ischemia, cardiac dilation and subsequent heart failure continue to occur in approximately 50 percent of post-infraction patients discharged from the hospital.
  • Various surgical approaches have been tried to treat the dilation of the ventricle by primarily reducing the ventricular volume. Some of these procedures involve removing or excluding dyskinetic and akinetic regions of the heart, then surgically joining the viable portions of the myocardial walls, typically with the use of a patch surgically placed in the walls using a Fontan stitch.
  • Typically, the exact placement of the patch has been visually determined using only a visual indication where the typically white scar tissue meets the typically red normal tissue. Location of the patch has been facilitated in a further procedure where a continuous suture has been placed around the ventricular wall to define a neck for receiving the patch. The neck has been formed in the white scar tissue rather than the soft viable muscle. This procedure has relied on cardioplegia methods to stop the beating of the heart and to aid in suture placement.
  • These surgical procedures have been met with some success as the ejection fraction has been increased, for example, from 24 percent to 42 percent. However, despite this level of success, it is often difficult for the surgeon to reconstruct the shape and size of the left ventricle. If the reconstructed ventricle is too small, the patient will not be able to pump enough oxygenated blood. If the reconstructed ventricle is too large, the ejection fraction may diminish. In addition to the size, the shape of the reconstructed ventricle is also important. If the left ventricle is reconstructed in a spherical shape, a twisting motion of the heart about its apex, which can account for as much as one half of the pumping action, is lost. As a consequence, the spherical shaped reconstructed ventricle must rely almost totally on the lateral squeezing action to pump blood. This lateral squeezing action is inefficient and very different from the more efficient twisting action of the heart. What is needed, therefore is a reliable method and apparatus to allow a surgeon to reconstruct the left ventricle to the appropriate shape, size and contour.
  • SUMMARY
  • In response to these and other problems, an improved apparatus and method is provided for restoring the geometry of the left ventricle to counteract the effects of cardiac remodeling. One embodiment of the present invention provides an apparatus and method to reconstruct an enlarged left ventricle of a human heart, using a shaper, having a size and shape substantially equal to the size and shape of an appropriate left ventricle, wherein the shaper is adapted to be temporarily placed into the enlarged left ventricle during a surgical procedure. Another aspect of one embodiment comprises a ventricular patch adapted for placement into the left ventricle of a heart made from a sheet of biocompatible material, and having a plurality of markings coupled to the sheet, wherein the markings are configured in distinct patterns for post operatively evaluating movement of the patch. In another aspect of one embodiment, a device is presented, comprising of a handle and a sizing template adapted to be coupled to the handle. Such components are also presented as a kit for use during ventricular restoration surgery.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates one embodiment of a process utilizing several aspects of the present invention.
  • FIG. 2 a is a side view of one embodiment of a shaping device.
  • FIG. 2 b is a side view of a balloon embodiment of a shaping device.
  • FIG. 2 c is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 d is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 e is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 f is a section view of another balloon embodiment of a shaping device.
  • FIG. 2 g is a side view of a wire frame embodiment of a shaping device in an expanded condition.
  • FIG. 2 h is a side view of a wire frame embodiment of a shaping device in an expanded condition.
  • FIG. 2 j is a section view cut transversely through the embodiment of FIG. 2 h.
  • FIG. 3 a is a top view of one embodiment of a patch.
  • FIG. 3 b is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 c is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 d is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 3 e is a top view of one embodiment of markings which may be coupled to the patch of FIG. 3 a.
  • FIG. 4 a is a top view of one embodiment of a set of sizers.
  • FIG. 4 b is a top view of one embodiment of a handle to be used with the set of sizers illustrated in FIG. 4 a.
  • FIG. 4 c is a detailed section view illustrating a connection between the handle and a sizer.
  • FIG. 4 d is a section view of one embodiment of a sizer.
  • FIG. 4 e is a section view of one embodiment of a sizer.
  • FIG. 4 f is a section view of one embodiment of a sizer.
  • FIG. 4 g is a top view of one embodiment of a sizer made of malleable wire.
  • FIG. 4 h is a side view of the sizer illustrated in FIG. 4 g.
  • FIG. 5 a is a top view of one embodiment of a patch holder.
  • FIG. 5 b is a top view of one embodiment of a suture hook.
  • FIG. 6 is a top view of one embodiment of a kit for surgically reshaping a ventricle.
  • FIG. 7 a illustrates one embodiment of a process utilizing several aspects of the present invention.
  • FIG. 7 b is a continuation of the process illustrated in FIG. 7 a.
  • DETAILED DESCRIPTION
  • An overview method of one embodiment is presented which introduces the primary components of one embodiment. A detailed discussion of these components then follows. Finally, a method of using the components is discussed in detail.
  • Overview:
  • Turning to FIG. 1, there is presented an overview method 100 for performing and using one embodiment of the present invention. A more complete discussion of this method will be presented below. The method 100 may use the following components: a shaping device 200 (FIG. 2 a), a patch 300 (FIG. 3 a), a sizer 402 a (FIG. 4 a), and a suture hook 520 (FIG. 5). Referring back to FIG. 1, at step 102, a surgeon determines the appropriate size for the patient's left ventricle based on the patient's height, weight, body surface area and other patient specific conditions. Once the patient's appropriate ventricle size has been determined, at step 104, the surgeon can then select the appropriate volume for the shaping device 200. At step 106, the surgeon opens up the chest cavity in a conventional manner. An incision is cut into the myocardial wall of an enlarged heart in step 108. At step 110, the surgeon may remove all or some of the non-viable tissue (i.e., the dyskinetic and akinetic areas) of the myocardium. A continuous round stitch, known in the art as a Fontan stitch, may then be woven into the ventricle, at step 114. The stitch produces an annular protrusion, which forms an opening. At step 116, the shaping device 200 may be inserted into the ventricle through this opening. The musculature of the myocardium may be pulled over the shaping device to form a left ventricle having a predetermined volume, shape and contour. The shaping device 200 may then be compressed and removed at step 120. At step 122, with the aid of the sizer 402 a, the surgeon may determine the preferred location of and size of the patch 300 which may be placed in the left ventricle. The patch 300 is then cut to size in step 124 and secured to the inside of the myocardium in step 126. At step 128, with the patch 300 suitably placed, the ventricle is closed by joining the myocardial walls over the patch.
  • Description of Components:
  • The Shaping Device:
  • FIG. 2 a illustrates one embodiment of a shaping device 200. In an inflated condition, the shaping device 200 is pre-shaped to generally model the appropriate volume and shape of the left ventricle.
  • The shape of the normal heart is of particular interest as it dramatically affects the way that the blood is pumped. The left ventricle which is the primary pumping chamber, is somewhat conical or apical in shape in that it is longer (long axis longest portion from aortic valve to apex) than it is wide (short axis widest portion from ventricle wall to septum) and descends from a base with a decreasing cross-sectional circumference to a point or apex. The left ventricle is further defined by a lateral and posterior ventricle wall and a septum, which extends between the auricles and the ventricles. The pumping of the blood from the left ventricle is accomplished by two types of motion. One of these motions is a simple squeezing motion, which occurs between the lateral wall and the septum. The squeezing motion occurs as a result of a thickening of the muscle fibers in the myocardium. This compresses the blood in the ventricle chamber and ejects it into the body. The thickness changes as the ventricle contracts. This is seen easily by echocardiogram and can be routinely measured.
  • The other type of motion is a twisting or writhing motion, which begins at the apex and rises toward the base. The rising writhing motion occurs because the heart muscle fibers run in a circular or spiral direction around the heart. When these fibers constrict, they cause the heart to twist initially at the small area of the apex, but progressively and ultimately to the wide area of the base. These squeezing and twisting motions are equally important, as they are each responsible for moving approximately one-half of the blood pumped. Turning now to FIG. 2 a, there is shown a shaping device 200 that allows the left ventricle to be reconstructed back to a pre-enlarged operating condition. When the surgeon uses shaping device 200 as a guide in reconstructing the left ventricle, the reconstructed heart can be formed closer to the size and shape of the pre-enlarged heart. Consequently, the heart performs better post operatively than with conventional methods. As illustrated, the shaping device 200 is generally conical or “tear drop” in shape. The length “L” of the shaping device 200 may vary with each patient and will typically be a function of the volume selected for the shaping device. Depending on the patient, the length “L” may be in the three to four inch range to generally match the length of the pre-enlarged left ventricle. A surgeon may select the appropriate volume for the shaping device by estimating the volume of the pre-enlarged left ventricle. The appropriate volume of the pre-enlarged left ventricle for a patient may be estimated to be 50 to 70 cc per square meter of body surface area. The body surface area may be estimated according to the following formula, as known in the art:
    BSA=0.001*71.84w 0.428 *h 0.725
    Where: BSA =body surface area,
      • w=body weight in kilograms, and
      • h=body height in centimeters.
  • The shaping device may be of an “appropriate shape” for a patient. In other words, the shaping device may be of a shape similar to the shape of the left ventricle. In one embodiment, the shaping device 200 may be a generally conical shaped object composed of portions of spherical elements having different radii. Referring back to FIG. 2 a, the illustrative embodiment of the shaping device may be divided lengthwise into six sections where each section is a length “L2” apart. L2, therefore, may be determined from the formula: L2=0.1665*L. At line “A-A”, a width W1 of the shaping device 200 is approximately 0.543*L. The back surface 202 of the shaping device 200 is generally shaped as a portion of a sphere, having a radius of 0.802*L. At a line “C-C”, a width W2 of the shaping device 200 is approximately 0.628*L. The side surfaces 204 a and 204 b are combinations of portions of spheres with different radii. Between the line A-A and the line C-C, the side surfaces 204 a and 204 b have a radius of 0.515 L.
  • At a line “E-E”, a width W3 of the shaping device 200 is 0.435*L. Between the line C-C and the line E-E, the side surfaces 204 a and 204 b have a radius of 0.945 L. The shaping device 200 narrows from the line designated “E-E” through a line designated as “F-F” to a vertex 206 at point “G”. It is important to note that the above discussion is illustrative of only one embodiment of the present invention and is not meant to limit the invention to the above ratios or shapes.
  • In some embodiments, such as illustrated in FIG. 2 b, the shaping device may be an inflatable balloon 201, having a thickness of in the range of 0.02 to 0.08 inches, preferably 0.03 inches. A distal end of a filler tube 208 may be coupled to a point 207 along the exterior surface of balloon 201. For instance, the point 207 could be located approximately ⅓ along balloon's 201 length, as illustrated in FIG. 2 b. In other embodiments, the filler tube 208 may be coupled vertex 206. Such tubes are well known in the art, and illustratively may be made of materials such as PVC. A proximal end of the filler tube 208 may be connected to a fluid reservoir, such as a syringe 210 which may inject a pre-specified amount of fluid into the balloon 201 through the filler tube 208. Also coupled to the distal end of the filler tube 208 may be a fluid control device such a stopcock 212. The injection of fluid through the filler tube 208 inflates the balloon 201 to an inflated condition, as illustrated in FIG. 2 b. Once inflated, the fluid inside the shaping device may be prevented from escaping by locking the stopcock 212. This allows the balloon 201 to stay inflated with the proper volume, shape and contour during the reconstruction procedure.
  • The fluid pressure inside the balloon 201 may also be monitored by a pressure transducer, such as a piezoelectric transducer (not shown) coupled to the filler tube 208 with a y-connection (not shown). In other words, one lead of the y-connection would be coupled to a pressure monitor and the other lead would be coupled to the fluid source. Alternatively, the pressure monitor could be coupled to a three way stopcock (not shown), which would monitor the pressure on the filler tube side of the three way stopcock.
  • The fluid used to fill the balloon 201 may be any one of a number of fluids, such as saline solution or distilled water. Alternatively, another embodiment could use a sealed balloon containing a silicone gel, such as a liquid methyl silicone resin capable of being vulcanized blended with a dimethyl silicone fluid. Such gels are available from Applied Silicon Inc. (Ventura, Calif.). An embodiment using a sealed balloon would not need an external fluid reservoir, such as syringe 210.
  • The balloon 201 may be conventionally formed on a mandrel (not shown) having dimensions corresponding to the shape, contour and size of the shaping device. As is known in the art, the mandrel can be made of metal, glass or a hardened gelatin. To form the balloon 201, the mandrel is dipped into a polymer solution, which leaves a thin polymer coating on the mandrel surface. After the polymer has cured, the balloon 201 is removed by peeling the thin coating off the mandrel or by flushing mandrel material out of the shaping device.
  • Shaping Device—Other Embodiments:
  • The shaping device of the present invention may be made out of a variety of materials in a number of configurations creating a number of embodiments. For instance if the shaping device is molded from a thermoplastic polymer such as PVC or polyethylene or a similar material, the balloon may be “non-expandable” when inflated. In other words, once the balloon is inflated, the balloon 201 will not significantly expand beyond the original shape. To illustrate, several shaping devices might have volumes ranging from 100 cc to 150 cc at 10 cc increments. If a surgeon predetermines that a patient's pre-enlarged left ventricle was 128 cc., then the surgeon might select a non-expandable balloon having a volume of 130 cc. A surgeon could also request a custom non-expandable balloon with a volume specifically sized for an individual patient.
  • In contrast, if the balloon 201 is made from an elastomeric material, the balloon 201 may significantly expand. Such elastomeric materials may include latex, polyurethane, silicone, and other elastomers sold under the trade names KRATON (Shell Chemical, New York, N.Y.), C-FLEX (Concept Polymer, Largo, Fla.) and SANTOPRENE (Monsanto, St. Louis, Mo.) Once the balloon is substantially inflated, the influx of additional fluid causes additional expansion of the balloon. Using this embodiment, the surgeon would simply inflate the balloon to a specific volume. The original shape of the balloon may be maintained during this expansion by selectively thickening the walls of the balloon. FIG. 2 c is a section view of an embodiment showing thickened walls of an “expandable balloon” 220. An insertion or distal end 222 of the balloon 220 has walls at a maximum thickness. From the line A-A, the wall thickness progressively decreases to a vertex 224 at point G. In some embodiments, the vertex 224 connects to the filler tube 208. The wall thickness will depend on the expansion range of the balloon. For example, for an expansion of 100 to 150 cc, the thickness of the balloon would vary from 0.01″ at a thin end to 0.05″ at the thick end. Thus, this size or volume of this embodiment may be controlled by controlling the amount and pressure of the fluid injected into the balloon 220.
  • In another embodiment, the shaping device could have walls that are relatively thick and are coupled to foam spacers or thermoplastic polymer pads surrounding the exterior of the balloon. Turning now to FIG. 2 d, there is shown a section view of an embodiment having polymer pads 232 a through 232 l coupled to the exterior of a balloon 230. In a substantially inflated condition, polymer pads 232 a-232 l provide a plurality of contact points: “A” through “L”. Contact points “A” though “L”, if connected, would define a space of approximately the same volume occupied by the balloon 201 (FIG. 2 a). Consequently, the balloon 230 would need less fluid for inflation and the polymer pads 232 a through 232 l would also provide puncture resistance.
  • In yet another embodiment, the shaping device could be a balloon within a balloon. FIG. 2 e illustrates such an embodiment. A balloon 250 is generally shown in FIG. 2 e. The balloon 250 comprises an outer balloon 252 and an inner balloon 254. In one embodiment, the inner balloon 254 is inflatable with a fluid, such as saline solution fluid. As in other embodiments, the inner balloon 254 may be inflated through the filler tube 208. A space 256 between the inner balloon 254 and the outer balloon 252 may be pre-filled with a gel 258, such as a silicone gel or saline solution.
  • FIG. 2 f is a section view illustrating another embodiment of a balloon 260 formed to be puncture resistant. In this embodiment, the wall 262 proximal to the vertex 206 is progressively thickened to protect the proximal side of the balloon 260 from punctures during the reconstruction procedure. In an alternative embodiment, the wall 262 could be coupled to protective pads located around the vertex 206 to protect the balloon 260 from punctures. In yet another embodiment, the balloon could be made from a thick, self sealing latex rubber. Such latex compounds are well known in the industry.
  • The shaping device is not limited to polymeric balloon embodiments. FIG. 2 g illustrates a shaping device 280 made from a wire skeleton or frame. The wire frame could be made from surgical grade stainless steel, titanium, tantalum, or nitinol, which is a commercially available nickel-titanium alloy material that has shape memory and is superelastic. Nitinol medical products are available from AMF of Reuilly, France, and Flexmedics Corp., of White Bear Lake, Minn.
  • The shaping device 280 illustrated in FIG. 2 g is in an expanded condition. Running through the center of shaping device 280 is a main shaft 282. The main shaft 282 has a distal end 284 and a proximal end 286. At the distal end 284 is a joint 288. Coupled to the joint 288 is a series of back ribs 290 a though 290 h (only back ribs 290 a through 290 e are visible in FIG. 2 g). Back ribs 290 a through 290 h are connected to front ribs 292 a-292 h by hinges 294 a though 294 h (only front ribs 292 a-292 e and hinges 294 a-294 e are visible in FIG. 2 f). The proximal end of front ribs 292 a through 292 e are connected to a collar 296 through a series of hinges (not shown) radially spaced around collar 296. The use of hinges around collar 296 encourages front ribs 292 a-292 h to form a convex angle with respect to shaft 282 at collar 296.
  • FIG. 2 h shows the shaping device 280 in a collapsed position. In a collapsed position, back ribs 290 a-290 h and front ribs 292 a-292 h surround shaft 282 as illustrated in FIG. 2 j. FIG. 2 j is a section view cut transversely through shaft 282 and the front ribs 292 a-292 h. In operation, once the shaping device 280 is inserted into the left ventricle, a surgeon may slide collar 296 along shaft 282 towards distal end 284. The force exerted on collar 296 will cause the ribs to buckle radially outward as illustrated in FIG. 2 g. Eventually, the front ribs 292 a-292 h will bend under the applied force. Because the front ribs 292 a-292 h are under stress, they will tend to push the collar 296 towards proximal end 286. A lock 294 prevents any desired movement towards proximal end 286. Thus, the collar 296 is held firmly in place along shaft 282 by the front ribs 292 a-292 h exerting a force through collar 296 to lock 294. The lock 294 is spring (not shown) activated and is designed such that the collar 296 may easily slide over the lock when moving from the proximal end 286 to the distal end 288. When the surgeon is ready to remove the shaping device 280, the surgeon may collapse the shaping device 280 by pressing down on lock 294 which will allow the collar 296 to slide past the lock 294 towards the proximal end 286.
  • Patch:
  • As will be explained in greater detail below, a patch is often used in the ventricle reconstruction procedure. A patch is made from sheet material and may be a variety of shapes, including circular, elliptical, or triangular, preferably sized and configured with a shape similar to a Fontan neck, as discussed below. As illustrated in FIG. 3 a, an elliptical patch 300 may have a length between 30 and 50 millimeters along a major axis 302 and a width along a minor axis 304 of between 20 and 30 millimeters. The preferable thickness of the patch is in the range of 0.3 to 0.7 mm. The water permeability is preferably less than 5 ml per cm sq. per minute at 120 mm Hg. The burst strength of the patch is preferably 30 to 35 kg/cm2. Finally, the 45° angle suture retention strength of the patch should be greater than 3 kg.
  • The sheet material for the patch 300 may be formed from a biocompatible synthetic material, for example, from polyester, Dacron (Hemoshield) manufactured by the DuPont Corporation, or polytetrafluoroethylene (Gortex). The sheet material may also be autologous pericardium, or some other fixed mammalium tissue such as bovine pericardium or porcine tissue. The biocompatible synthetic material patch may be collagen impregnated to assist in hemostasis, or it may be sprayed with a hemostatic sealant to achieve better and instantaneous hemostasis.
  • The patch may have markings that enable the movement and position of the patch to be post-operatively observed and analyzed under imaging systems, such as Magnetic Resonance Imaging (“MRI”), x-ray machines, fluoroscopy or other external visualization methods, for post-operative clinical evaluation. Such markings will allow identification of the patch and allow for analysis of the heart's contractility in future post-operative evaluations.
  • The markings may be radiopaque. Radiopaque markings are made from material that are impenetrable to radiation such as x-rays. Radiopaque markings may be applied to the patch material in a wide variety of methods. For instance, if the patch material is from a woven fabric, then radiopaque threads could be woven into the fabric at regular intervals. Such radiopaque threads could be metal and made from alloys of gold, nitinol, platinum, or stainless steel. Radiopaque threads could also be made of a biocompatible polymeric material mixed with a metal powder, such as barium sulfate. Radiopaque markings could also be imprinted onto the fabric with radiopaque ink. Such ink is available from Creative Imprints Inc., (Norton, Mass.).
  • Other techniques for marking the patch 300 might include chemical vapor deposition, physical vapor deposition, electroplating and ion-beam assisted deposition. In ion-beam assisted deposition, an electron beam evaporator is used to create a vapor of atoms that coats the surface of the material.
  • Radiopaque threads might interfere with MRI scans because MRI is extremely sensitive to metal and metal can substantially mask MRI signals. However, if metal markings are made sufficiently small, they will show as bands in an MRI scan. Using metal fibers 0.1 mm to 0.05 mm to create the grid or pattern by weaving into the patch can make a patch MRI sensitive. Also, the metal can be applied to the patch by ion deposition which could deposit a layer of metal 0.01 mm thick onto the patch material. Small tubular strands filled with fatty acids could also be used as be used as MRI sensitive markings. Such strands could be woven into the patch material.
  • The markings may be Positron Emission Tomography (“PET”) sensitive by making the markings slightly radioactive. However, such markings would probably only be useful for a relatively short time frame after the procedure because of radioactive decay.
  • The markings may also be attached to the material by a variety of mechanical means such as sewing or weaving the markings into patch material or using microclips. Similarly, the markings such as metal threads may also be attached to the material by adhesive means, such as a bio-compatible glue. Such bio-compatible glues are available from Bioglue, Cryolife Inc. (Kennesaw, Ga.) or Cyanoacrylate, by Loc Tite Corp.
  • In order to be useful, the markings must be arranged in a pattern that allows post operative evaluation. One such pattern is a series of equally spaced substantially parallel lines as illustrated in FIG. 3 b. Another pattern is a grid of substantially parallel lines as illustrated in FIG. 3 c. The distance between these parallel lines may be in standard units, such as 1 centimeter. Another pattern could be in the form of concentric circles, as illustrated in FIG. 3 d. Yet, another pattern could be a series of lines radiating from a single point at, for instance, a set angle apart. Such a pattern is illustrated in FIG. 3 e.
  • Sizers:
  • Turning now to FIG. 4 a, there is illustrated a set of sizers 402 a-402 d. The sizers 402 a-402 d are shaped to be the approximate size of the patch 300 (FIG. 3 a). Similar to the patch, the sizers 402 a-402 d will be of various geometries, length and width combinations. For illustrative purposes, the sizers 402 a-402 d discussed herein will be elliptical in shape. For posterior repairs to the ventricle, however, the sizers may have a general triangular shape. Referring back to FIG. 4 a, the length of the sizers along a major axis 403 may be in the range of 2 to 7 cm in length. The length along a minor axis 405 may be 1 to 5 cm in length. The sizers may have a connection 406 for attachment to a handle 404 (FIG. 4 b). The sizers 402 a-402 d can be made out of plastic or stainless steel or any rigid material. Four sizers 402 a-402 d are illustrated in FIG. 4 a, however, any number of sizers in a variety of could be provided.
  • Turning now to FIG. 4 b, the handle 404 may also be made from stainless steel, plastic or any other suitable material. The handle 404 includes a shaft 408 having a proximal end 410 and a distal end 412. The distal end 412 couples to the connection 406 of the sizers 402 a-402 d. The proximal end 410 is coupled to a hand grip 414. The hand grip 414 is sized to fit a human hand. Such hand grips are well known in the art. A surgeon may connect any of the sizers 402 a-402 d to the handle 404. The use of handle 404 with a sizer allows the surgeon to easily estimate the size of the opening to be patched by holding the sizer up to and into the opening. If the sizer is too small, another one may be selected. This process may be repeated until the surgeon feels he has a sizer of the correct shape and size. As will be explained in greater detail below, once the proper size has been determined the sizer may be placed on material and be used as a template to cut the patch 300 to the appropriate size.
  • FIG. 4 c is a section view illustrating the connection 406 between the distal end 412 of shaft 408 and the sizer 402 a. In this embodiment, the connection 406 comprises a circular opening 422. Embedded in the walls of the opening 422 and running through the opening 422 is a rod 420. The rod 420 may be made of surgical stainless steel or another appropriate rigid material. In the illustrative embodiment, the distal end 412 includes a slot 425 with angular walls forming two flanges 423 a and 423 b. At the base of the slot 425 is a circular groove. The circular grove runs generally parallel to the slot 425 and has an interior diameter slightly larger than the exterior diameter of rod 420. The base of the slot 425 is slightly smaller than the diameter of rod 420. When distal end 412 is inserted into circular groove, flanges 423 a and 423 b slide over rod 420 until rod 420 is in the circular groove. Thus, flanges 423 a and 423 b are “snapped” over rod 420, and thus, will keep rod 420 in the cylindrical groove. The sizer 402 a may rotate with respect to shaft 408. The sizer 402 a may be removed from handle 404 by pulling on the sizer 402 a which causes a sufficient amount of force on rod 420 to lift flanges 423 a and 423 b over rod 420. In other embodiments, connection 406 may be a screw connection.
  • In another embodiment, the sizers may have a cutting edge which can be used to cut the patch 300 to the appropriate shape. Turning now to FIG. 4 d, a sizer 430 is shown connected to the handle 408. In this embodiment, the sizer 430 may have a ridge 432 concentric to the shape of the sizer 430. The ridge 432 allows a surgeon to accurately estimate the size of the opening by placing the ridge 432 into the opening. The sizer 430 may also have a circumferential flange or lip 434 around the perimeter of the sizer to assist in defining the patch size. The patch will typically be slightly larger than the size of the opening. The width of the lip 434 will preferably have a constant width around its circumference, typically in the range between 5 and 8 centimeters. A cutting edge 434 may also be coupled to the perimeter of the lip. In operation, the surgeon may use the sizer as illustrated in FIG. 4 d to estimate the size of the opening, remove the sizer 430 from the handle 408, turn the handle over with respect to the handle 408, and re-attach the sizer 430 to the handle 408. The cutting edge 434 may then be used to cut the patch material to the correct size and shape by pressing the cutting edge into the patch material.
  • A set of cutting dies could also be provided which corresponds to the set of sizers. In other words, for each sizer provided in a set of sizers, there would be a corresponding cutting die, sized to be slightly larger than the sizer. Once a surgeon has determined the correct sizer, he could then select the corresponding cutting die and use the cutting die to cut the patch material to the appropriate size. Alternatively, a set of pre-cut patches could be provided, each pre-cut patch corresponding to a particular sizer in the set of sizers. The use of pre-cut patches would eliminate the need to cut the patch material to the required shape. The pre-cut patches may also have pre-printed suture lines which may be used as a guide for the surgeon when attaching the patch to the heart.
  • FIG. 4 e illustrates an embodiment of a sizer 440 having a protrusion 442 concentric to the shape of the sizer 440. The protrusion 442 may also be used to define a suture line on the patch material by pressing the protrusion 442 against the patch material causing an indentation in the patch material which the surgeon can use as a guide to suture the patch. Turning now to FIG. 4 f, which illustrates embodiment of a sizer 450 having a slot or groove 452 concentric to the shape of the sizer. The groove 452 may be used by the surgeon to define a suture line by allowing the surgeon to use a marking instrument, such as a pen, to trace the suture line on the patch material.
  • FIG. 4 g illustrates yet another embodiment of a sizer. The sizer 460 may be a malleable wire 462 coupled to movable legs 464 a-464 d (464 a and 464 b are visible in FIG. 4 g). The moveable legs 464 a-464 d are coupled to a handle 466. The handle 466 includes a shaft 468 having a proximal end 470 and a distal end 472. The distal end 472 couples to the movable legs 464 a-464 d. The proximal end 470 is coupled to a hand grip 474. The hand grip 474 is similar to the handgrip 414 of FIG. 4 b. FIG. 4 h is a section view of the sizer 460 cut through the movable legs 464 a-464 d. The malleable wire 462 may be manipulated by the surgeon into any appropriate shape. Additionally, because one end 466 of the malleable wire 462 is free to slide past the moveable legs 464 a and 464 d, the perimeter of the shape formed by the wire may be lengthened or shortened as desired.
  • Patch Holder:
  • Turning now to FIG. 5 a, there is illustrated a patch holder 500. The patch holder 500 comprises a patch plate 502 coupled to legs 504 a-504 d (504 a and 504 b are visible in FIG. 5 a). The legs 504 a-504 d are coupled to a handle 506, which is similar to handle 466 discussed above. The patch plate 502 has an adhesive means on side 508, such as an adhesive backing or nylon hooks, which temporarily adheres to the patch. In operation, after a surgeon has constructed the appropriate patch, the surgeon may use patch holder 500 to place the patch into the opening, after suturing has begun, the patch holder may be removed, leaving the patch in place.
  • Suture Hook:
  • Turning now to FIG. 5 b, there is illustrated a suture hook 520. The suture hook 520 is “L” shaped and made of stainless steel, plastic or another rigid material. The suture hook 520 has a long leg 522 which may be approximately 6 inches long. Coupled to long leg 522, is short leg 524 which may be in the range of one-eighth to one-quarter inch long. The suture hook 520 is adapted to be used to pull up on the sutures in the patch 300 to secure the patch 300 to the heart.
  • Kit:
  • In yet another embodiment of the present invention, a kit 600 for surgically reshaping the left ventricle of the heart is illustrated in FIG. 6. The kit 600 may include any of the components discussed above, including: the balloon 201 coupled to the syringe 210, a set of the sizers 402 a-402 d in various shapes and sizes, a handle 404 to attach to the sizers 402 a-402 d, material 602 for creating the patch 300 (not shown), the suture hook 520 and, the patch holder 500 (not shown). The components of the kit 600 may be packaged in a sterile manner as known in the relevant art.
  • Operation:
  • With the primary purpose of restoring the ventricle's size, shape and contour, the intent of the procedure initially is to remove that portion of the wall, which is not capable of contracting. Such portions include the scarred dyskinetic segments, which are easy to see visually, and may also include akinetic segments, which do not contract.
  • Referring now to FIG. 7, which illustrates generally a method 700 for performing and using at least one embodiment of the present invention. At step 702, a surgeon determines the appropriate size for the patient's left ventricle based on the patient's height, weight, body surface area and other patient specific conditions (as discussed previously in reference to FIG. 2 a). Once the patient's appropriate ventricle size has been determined, at step 704, the surgeon can then select the appropriate volume for the shaping device.
  • In step 706, the patient's chest cavity is opened up in a conventional manner. In step 708, an incision is cut into the myocardial wall of the dilated heart. If the surrounding tissue is dyskinetic, it will typically be formed entirely of thin, elastic scar tissue. It is the elasticity of this scar tissue, which causes the detrimental ballooning, or bulging effects previously discussed.
  • In step 710, a determination as to where the akinetic portions of the tissue begin and end must be made. The determination between viable and non viable tissue can be made by multiple methods, including: visual inspection, electrical methods, marking with dyes, echocardiography, radionuclear imaging, and palpation of a beating heart.
  • The electrical methods might include the use of an electromyogram which detects electrical impulses from active tissue to distinguish between the akinetic and viable tissue. Positron Emission Tomography (PET) scanning, Single Proton Emissions Computer Tomography and Electrical Mapping Electrophysiology are all other examples of a method to determine viable tissue from akinetic tissue with by electrical means. With Electrical Mapping Electrophysiology, a catheter is inserted into the heart to find areas void of electrical activity.
  • Marking with dyes can be accomplished by staining the myocardium tissue with a dye that adheres to viable tissue and does not adhere to scar tissue. Triphenyltetrazolium chloride, Tropinin I or T, and Creatine Kinase are all examples of dyes that perform this marking function.
  • Once the extent of the non-viable areas are determined, in step 712, the portion of the tissue in the ventricle and septal walls may be excised from the epicardium from the incision to the borderline separating akinetic tissue from viable tissue. This border between akinetic and viable tissue becomes the preferred location of the patch and forms an imaginary circumferential line between the non viable areas and viable areas of the myocardium.
  • In step 714, the preferred location of the patch 300 is been determined relative to the circumferential line. In step 716, a continuous Fontan stitch may be placed in proximity to the line, along the long axis of the heart. The Fontan stitch produces an annular protrusion, which forms a neck relative to the circumferential line. The annular protrusion may be further defined by placing a rim support around its perimeter. This neck initially may have a round circular configuration. A second Fontan stitch may be placed 90 degrees from the initial stitch along the short axis of the heart. Other stitches may be placed as needed to form the heart to the shaping device. The stitch will serve to shape the heart along the short axis of the heart if needed.
  • In step 718, the shaping device 200 may then be inserted into the ventricle. The shaping device 200 is then inflated or expanded, the volume of which is equivalent to the appropriate volume of the ventricle for the patient. The shaping device 200 provides the model upon which the ventricle can be shaped and contoured through the use of the Fontan suture in step 720. The Fontan suture may then tightened with the aid of the suture hook 520, in step 722. As the suture or sutures are tightened, the musculature of the myocardium will form the physiologically correct volume, shape and contour over the shaping device. The appropriately oval-shaped opening in the neck defines the area where the patch will be placed. Once the suture is tightened down, the shaping device 200 may be collapsed and removed in step 724.
  • The size of the opening in the neck formed by the Fontan stitch will vary from patient to patient. If the patch 300 is used to close the ventricle, the surgeon should determine the size of the patch to be used (step 726). To determine the appropriate size of the patch, the surgeon may connect any of the sizers 402 a-402 d to the handle 404 to measure the size of the opening, and thus, the size patch 300 that is needed to fit into the neck formed by the Fontan stitch or stitches. In step 728, the surgeon may then construct a patch. In embodiments with different sizers, once the proper sizer has been selected, the sizer can be placed on the patch and be used as a template to cut the patch 300 to the appropriate size. Alternatively, a surgeon may select a precut patch.
  • In a preferred method for placing the patch, continuous or interrupted sutures can be threaded through the rim covered annular protrusion. The rim covering acts as a large continuous pledget along the perimeter. After the patch has been moved into position on the neck, the sutures can be tied, in step 730.
  • Alternatively, in cases of extensive nonfibrotic trabecular tissue on the lateral ventricle, another suture method can be placement of mattressed braided sutures over a pericardial strip from outside the ventricle to its interior through the inner oval of the patch. This procedure can be done in conjunction with other procedures such as: Mitral valve repair, ablation of ventricular arrhythmias for treatment of refractory ischemic ventricular tachycardia.
  • With the patch, suitably placed, in step 732, the suture line can be sprayed with a hemostatic agent or an agent can be applied to achieve better and instantaneous hemostasis. In step 734, the operative site can be closed by joining or folding over the myocardial walls. Care should be taken not to distort the right ventricle by folding the septum wall over the ventricular wall. Alternatively, the lateral wall can be disposed interiorly of the septum wall so a majority of the force on the patch is diverted to the lateral wall. These walls can be overlapped in close proximity to the patch in order to avoid creating any cavity between the patch and the walls.
  • When air evacuation is confirmed by transesophageal echo, the patient can be weaned off bypass usually with minimal, if any inotropic support. Decannulasation may be accomplished with conventional methods (step 736).
  • As is well known, the human heart contains an electrical conduction system which sends electrical impulses to spark the heart muscle into regular cycles of contraction. This conduction system includes a Sinoatrial node (SA node), Atrioventricular Node (AV node), and Purkinie Fibers which act as conduits for the electrical pulses. The SA node is located in the right atrium. The electrical impulse leaves the SA node and travels to the right and left Atria, causing them to contract together. This takes 0.04 seconds. There is now a natural delay to allow the Atria to contract and the Ventricles to fill up with blood. The electrical impulse has now traveled to the Atrioventricular Node (AV node). The electrical impulse now goes to the Bundle of His, then it divides into the Right and Left Bundle Branches where it rapidly spreads using Purkinje Fibers to the muscles of the Right and Left Ventricle, causing them to contract at the same time.
  • Because ventricular restoration may compromise the conduction system due to the fact that a ventricle portion has been severed or excluded, the pacing or rhythm of the impulses between the right and left ventricles of the heart may get out of synchronization after ventricular restoration. This asynchronous pacing contributes to a reduced output by the left ventricle. Thus, restoring or assuring synchronization would assist the reconstructed left ventricle to maximize the output of the left ventricle. Synchronization may be restored or controlled by implanting a pacemaker or a Biventricular pacing device (“BVP”) before closing the chest cavity.
  • A pacemaker comprises: (1) an implantable controller that sets the heart rate to the desired interval, and (2) two leads that deliver electrical impulses to specific regions of the heart (i.e., one lead is placed in the right atrium and the second lead in right ventricle) to artificially cause contractions of the ventricle at the appropriate time and synchronization. In contrast, BVPs have a third lead designed to conduct signals directly into the left ventricle. When using a BVP, one lead is placed in the right atrium, the second lead in right ventricle, and third lead is placed to pace the left ventricle (i.e., in a tributary of the coronary sinus in the left ventricle). Thus, with a BVP, simultaneous electrical impulses are given to both left and right ventricles so the time delay in traveling of electrical impulse is significantly reduced which aids in restoring the normal physiology of the heart and improves the pumping action of the heart.
  • Pacemakers and biventricular pacing devices are available from Medtronic, Inc. (Minneapolis, Minn.), Guidant Corporation (Menlo Park, Calif.), and St. Jude Medical Inc. (St. Paul, Minn.).
  • The mortality associated with ventricular restoration is primarily from sudden death caused from extremely fast arrthymias. The higher risk of arrthymias may be caused from the removal of a portion of the left ventricle. This risk may be prevented by implanting a defibrillator at the time of the ventricle restoration. The automatic implantable cardioverter/defibrillator is commonly referred to as an AICD. The AICD is a device that is similar to a pacemaker, but continuously monitors the heart rhythm. If the AICD detects an abnormally fast or slow heart rhythm, it either electrically paces the heart very fast or delivers a small electrical shock to the heart to convert the heart rhythm back to normal.
  • Some BVP devices have defibrillators built into the circuitry that controls the pacing. Implanting a bi-ventricular pacing device with defibrillator after surgical ventricular restoration will not only optimize the output of the ventricle but also prevent many sudden deaths.
  • After a BVP has been installed in step 738, closure of the chest cavity may be accomplished in step 740 by conventional methods.
  • It is further understood that other modifications, changes and substitutions are intended in the foregoing disclosure and in some instances some features of the disclosure will be employed without corresponding use of other features. Accordingly, it is appropriate that the appended claims be construed broadly and in a manner consistent with the scope of the disclosure.

Claims (21)

1-28. (canceled)
29. A method for reshaping an enlarged left ventricle of a human heart, comprising:
positioning a shaper in the left ventricle, wherein the left ventricle has a first shape;
using the shaper as a model to reshape at least a portion of the left ventricle such that the reshaped left ventricle has a second shape; and
removing the shaper from the left ventricle.
30. The method of claim 29, wherein the second shape of the left ventricle displays an increased efficiency relative to the first shape of the left ventricle.
31. The method of claim 29, wherein at least a portion of the second shape substantially corresponds to at least a portion of a size of the shaper, and wherein at least a portion of the second shape substantially corresponds to at least a portion of a shape of the shaper.
32. The method of claim 29, wherein the shaper has a short axis and a long axis, and wherein the ratio of the short axis to the long axis is about 0.3 to about 0.7.
33. The method of claim 29, wherein the shaper is substantially ellipsoid in shape.
34. The method of claim 29, wherein the shaper is substantially pear shaped.
35. The method of claim 29, wherein the shaper is substantially tear drop shaped.
36. The method of claim 29, further comprising demarking between non-viable tissue and viable tissue of the left ventricle.
37. The method of claim 29, further comprising:
engaging a wall of the left ventricle of a beating heart to sense tactile feedback; and
determining a demarcation line between non-viable tissue and viable tissue of the left ventricle.
38. The method of claim 29, further comprising excluding at least some of the non-viable tissue of the left ventricle.
39. The method of claim 29, further comprising:
determining a demarcation line between non-viable tissue and viable tissue of the left ventricle; and
excluding at least some of the non-viable tissue;
placing at least one suture along at least a portion of the demarcation line; and
pulling the suture such that the left ventricle is pulled around the shaper.
40. The method of claim 39, further comprising attaching a patch along at least a portion of one of the demarcation lines.
41. The method of claim 29, further comprising attaching a patch to an interior of the left ventricle.
42. The method of claim 29, further comprising excluding at least some scar tissue from viable tissue of the left ventricle.
43. A method for reshaping a left ventricle of a human heart, comprising:
positioning a shaper in the left ventricle; and
reshaping at least a portion of the left ventricle about the shaper such that at least a portion of the left ventricle substantially conforms to a predetermined shape of the shaper.
44. The method of claim 43, further comprising:
determining a demarcation line between non-viable tissue and viable tissue;
excluding at least some of the non-viable tissue;
placing at least one suture along at least a portion of the demarcation line; and
pulling the suture such that the left ventricle is pulled around the shaper.
45. The method of claim 44, wherein the determining of the demarcation line further comprises engaging a wall of the left ventricle of a beating heart to sense tactile feedback.
46. The method of claim 44, further comprising attaching a patch along at least a portion of one of the demarcation lines.
47. The method of claim 43, further comprising attaching a patch to an interior of the left ventricle.
48. The method of claim 43, further comprising excluding scar tissue from viable tissue.
US11/244,865 2001-02-28 2005-10-06 Ventricular restoration shaping apparatus and method of use Abandoned US20060137697A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/244,865 US20060137697A1 (en) 2001-02-28 2005-10-06 Ventricular restoration shaping apparatus and method of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27207301P 2001-02-28 2001-02-28
US09/864,510 US6994093B2 (en) 2001-02-28 2001-05-24 Ventricular restoration shaping apparatus and method of use
US11/244,865 US20060137697A1 (en) 2001-02-28 2005-10-06 Ventricular restoration shaping apparatus and method of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/864,510 Continuation US6994093B2 (en) 2001-02-28 2001-05-24 Ventricular restoration shaping apparatus and method of use

Publications (1)

Publication Number Publication Date
US20060137697A1 true US20060137697A1 (en) 2006-06-29

Family

ID=26955284

Family Applications (8)

Application Number Title Priority Date Filing Date
US09/864,503 Expired - Fee Related US6702763B2 (en) 2001-02-28 2001-05-24 Sizing apparatus and method for use during ventricular restoration
US09/864,794 Expired - Fee Related US6681773B2 (en) 2001-02-28 2001-05-24 Kit and method for use during ventricular restoration
US09/864,510 Expired - Fee Related US6994093B2 (en) 2001-02-28 2001-05-24 Ventricular restoration shaping apparatus and method of use
US10/210,504 Abandoned US20030045896A1 (en) 2001-02-28 2002-07-31 Method of using a ventricular restoration shaping apparatus
US10/210,737 Abandoned US20030050659A1 (en) 2001-02-28 2002-07-31 Ventricular restoration shaping apparatus
US10/454,978 Expired - Fee Related US6959711B2 (en) 2001-02-28 2003-06-05 Kit and method for use during ventricular restoration
US11/113,611 Abandoned US20050278024A1 (en) 2001-02-28 2005-04-25 Kit and method for use during ventricular restoration
US11/244,865 Abandoned US20060137697A1 (en) 2001-02-28 2005-10-06 Ventricular restoration shaping apparatus and method of use

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US09/864,503 Expired - Fee Related US6702763B2 (en) 2001-02-28 2001-05-24 Sizing apparatus and method for use during ventricular restoration
US09/864,794 Expired - Fee Related US6681773B2 (en) 2001-02-28 2001-05-24 Kit and method for use during ventricular restoration
US09/864,510 Expired - Fee Related US6994093B2 (en) 2001-02-28 2001-05-24 Ventricular restoration shaping apparatus and method of use
US10/210,504 Abandoned US20030045896A1 (en) 2001-02-28 2002-07-31 Method of using a ventricular restoration shaping apparatus
US10/210,737 Abandoned US20030050659A1 (en) 2001-02-28 2002-07-31 Ventricular restoration shaping apparatus
US10/454,978 Expired - Fee Related US6959711B2 (en) 2001-02-28 2003-06-05 Kit and method for use during ventricular restoration
US11/113,611 Abandoned US20050278024A1 (en) 2001-02-28 2005-04-25 Kit and method for use during ventricular restoration

Country Status (1)

Country Link
US (8) US6702763B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060247672A1 (en) * 2005-04-27 2006-11-02 Vidlund Robert M Devices and methods for pericardial access
US7666224B2 (en) 2002-11-12 2010-02-23 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US7678145B2 (en) 2002-01-09 2010-03-16 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
CN103340663A (en) * 2013-06-17 2013-10-09 李宝童 Capsule type coronary oppressing device and method for manufacturing chronic myocardial ischemia animal model
WO2017083133A1 (en) * 2015-11-12 2017-05-18 Sonacare Medical Llc Tissue stabilization for therapeutic ultrasound

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7213601B2 (en) * 1993-02-22 2007-05-08 Heartport, Inc Minimally-invasive devices and methods for treatment of congestive heart failure
US20050131269A1 (en) * 1995-06-07 2005-06-16 Talmadge Karen D. System and method for delivering a therapeutic agent for bone disease
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
US6406420B1 (en) * 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6332893B1 (en) * 1997-12-17 2001-12-25 Myocor, Inc. Valve to myocardium tension members device and method
US7491232B2 (en) 1998-09-18 2009-02-17 Aptus Endosystems, Inc. Catheter-based fastener implantation apparatus and methods with implantation force resolution
US6260552B1 (en) * 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US7582051B2 (en) * 2005-06-10 2009-09-01 Cardiokinetix, Inc. Peripheral seal for a ventricular partitioning device
US20060229491A1 (en) * 2002-08-01 2006-10-12 Cardiokinetix, Inc. Method for treating myocardial rupture
US7674222B2 (en) * 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7887477B2 (en) * 1999-08-09 2011-02-15 Cardiokinetix, Inc. Method of improving cardiac function using a porous membrane
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8257428B2 (en) * 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US6537198B1 (en) * 2000-03-21 2003-03-25 Myocor, Inc. Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) * 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US7762943B2 (en) * 2004-03-03 2010-07-27 Cardiokinetix, Inc. Inflatable ventricular partitioning device
US7399271B2 (en) * 2004-01-09 2008-07-15 Cardiokinetix, Inc. Ventricular partitioning device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US8398537B2 (en) * 2005-06-10 2013-03-19 Cardiokinetix, Inc. Peripheral seal for a ventricular partitioning device
US7862500B2 (en) * 2002-08-01 2011-01-04 Cardiokinetix, Inc. Multiple partitioning devices for heart treatment
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US20060030881A1 (en) * 2004-08-05 2006-02-09 Cardiokinetix, Inc. Ventricular partitioning device
US6616684B1 (en) * 2000-10-06 2003-09-09 Myocor, Inc. Endovascular splinting devices and methods
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
US6702763B2 (en) * 2001-02-28 2004-03-09 Chase Medical, L.P. Sizing apparatus and method for use during ventricular restoration
US20020133227A1 (en) * 2001-02-28 2002-09-19 Gregory Murphy Ventricular restoration patch apparatus and method of use
US20030181940A1 (en) * 2001-02-28 2003-09-25 Gregory Murphy Ventricular restoration shaping apparatus and method of use
US7441342B2 (en) * 2001-04-24 2008-10-28 Chf Technologies, Inc. System and method for sizing a heart for treating congestive heart failure
US20080114394A1 (en) * 2001-04-24 2008-05-15 Houser Russell A Arteriotomy Closure Devices and Techniques
US20090143808A1 (en) * 2001-04-24 2009-06-04 Houser Russell A Guided Tissue Cutting Device, Method of Use and Kits Therefor
US20050113810A1 (en) * 2001-04-24 2005-05-26 Houser Russell A. Shaping suture for treating congestive heart failure
US20050096498A1 (en) * 2001-04-24 2005-05-05 Houser Russell A. Sizing and shaping device for treating congestive heart failure
US20050113811A1 (en) * 2001-04-24 2005-05-26 Houser Russell A. Method and devices for treating ischemic congestive heart failure
US8961541B2 (en) * 2007-12-03 2015-02-24 Cardio Vascular Technologies Inc. Vascular closure devices, systems, and methods of use
US8992567B1 (en) 2001-04-24 2015-03-31 Cardiovascular Technologies Inc. Compressible, deformable, or deflectable tissue closure devices and method of manufacture
US20040243170A1 (en) * 2001-09-05 2004-12-02 Mitta Suresh Method and device for percutaneous surgical ventricular repair
US20060025800A1 (en) * 2001-09-05 2006-02-02 Mitta Suresh Method and device for surgical ventricular repair
US7485088B2 (en) * 2001-09-05 2009-02-03 Chase Medical L.P. Method and device for percutaneous surgical ventricular repair
US20110087320A1 (en) * 2001-11-28 2011-04-14 Aptus Endosystems, Inc. Devices, Systems, and Methods for Prosthesis Delivery and Implantation, Including a Prosthesis Assembly
WO2003045283A1 (en) 2001-11-28 2003-06-05 Aptus Endosystems, Inc. Endovascular aneurysm repair system
US9320503B2 (en) 2001-11-28 2016-04-26 Medtronic Vascular, Inc. Devices, system, and methods for guiding an operative tool into an interior body region
US20050177180A1 (en) * 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US20070073389A1 (en) * 2001-11-28 2007-03-29 Aptus Endosystems, Inc. Endovascular aneurysm devices, systems, and methods
US8231639B2 (en) 2001-11-28 2012-07-31 Aptus Endosystems, Inc. Systems and methods for attaching a prosthesis within a body lumen or hollow organ
US20090099650A1 (en) * 2001-11-28 2009-04-16 Lee Bolduc Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US20030233022A1 (en) * 2002-06-12 2003-12-18 Vidlund Robert M. Devices and methods for heart valve treatment
US20050125012A1 (en) * 2002-06-28 2005-06-09 Houser Russell A. Hemostatic patch for treating congestive heart failure
US7247134B2 (en) * 2002-11-12 2007-07-24 Myocor, Inc. Devices and methods for heart valve treatment
US7513867B2 (en) * 2003-07-16 2009-04-07 Kardium, Inc. Methods and devices for altering blood flow through the left ventricle
US6958077B2 (en) * 2003-07-29 2005-10-25 Loubert Suddaby Inflatable nuclear prosthesis
DE202004021943U1 (en) 2003-09-12 2013-05-13 Vessix Vascular, Inc. Selectable eccentric remodeling and / or ablation of atherosclerotic material
US7641686B2 (en) * 2004-04-23 2010-01-05 Direct Flow Medical, Inc. Percutaneous heart valve with stentless support
EP2422751A3 (en) * 2004-05-05 2013-01-02 Direct Flow Medical, Inc. Unstented heart valve with formed in place support structure
US20050288691A1 (en) * 2004-06-28 2005-12-29 Leiboff Arnold R Hernia patch
US7972292B2 (en) 2005-07-06 2011-07-05 Percutaneous Systems, Inc. Methods and apparatus for deploying ureteral stents
US7883516B2 (en) * 2004-07-07 2011-02-08 Percutaneous Systems, Inc. Methods for removing kidney stones from the ureter
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US20060173300A1 (en) * 2005-01-11 2006-08-03 Aga Medical Corp. Open structure sizing device
US20060167386A1 (en) * 2005-01-24 2006-07-27 Drake Daniel H Blood vessel graft sizer
US7320665B2 (en) 2005-03-02 2008-01-22 Venkataramana Vijay Cardiac Ventricular Geometry Restoration Device and Treatment for Heart Failure
US20060199995A1 (en) * 2005-03-02 2006-09-07 Venkataramana Vijay Percutaneous cardiac ventricular geometry restoration device and treatment for heart failure
US20060247491A1 (en) * 2005-04-27 2006-11-02 Vidlund Robert M Devices and methods for heart valve treatment
US20060247764A1 (en) * 2005-04-27 2006-11-02 Bioventrix, A Chf Technologies Company, Inc. A Carlifornia Corporation System and method for sizing a heart for treating congestive heart failure
US20070042326A1 (en) * 2005-06-01 2007-02-22 Osseous Technologies Of America Collagen antral membrane expander
CA2610669A1 (en) * 2005-06-07 2006-12-14 Direct Flow Medical, Inc. Stentless aortic valve replacement with high radial strength
US7383639B2 (en) * 2005-07-12 2008-06-10 Medtronic Spine Llc Measurement instrument for percutaneous surgery
CN101466316B (en) 2005-10-20 2012-06-27 阿普特斯内系统公司 Devices systems and methods for prosthesis delivery and implantation including the use of a fastener tool
US7749249B2 (en) * 2006-02-21 2010-07-06 Kardium Inc. Method and device for closing holes in tissue
US8287503B2 (en) 2006-03-13 2012-10-16 Applied Medical Resources Corporation Balloon trocar
US8147453B2 (en) 2006-03-13 2012-04-03 Applied Medical Resources Corporation Balloon trocar
US20070219516A1 (en) * 2006-03-14 2007-09-20 Tyco Healthcare Group Lp X-ray detectable element for association with surgical absorbent substrates and method of making
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
ES2524303T3 (en) 2006-05-08 2014-12-05 C.R. Bard, Inc. User interface and methods for an ultrasound presentation device
US20070270688A1 (en) 2006-05-19 2007-11-22 Daniel Gelbart Automatic atherectomy system
US8449605B2 (en) * 2006-06-28 2013-05-28 Kardium Inc. Method for anchoring a mitral valve
US9119633B2 (en) 2006-06-28 2015-09-01 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US11389232B2 (en) 2006-06-28 2022-07-19 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US8920411B2 (en) 2006-06-28 2014-12-30 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US10028783B2 (en) 2006-06-28 2018-07-24 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US7837610B2 (en) * 2006-08-02 2010-11-23 Kardium Inc. System for improving diastolic dysfunction
US8694077B2 (en) 2006-10-06 2014-04-08 The Cleveland Clinic Foundation Apparatus and method for targeting a body tissue
US8019404B2 (en) * 2006-10-06 2011-09-13 The Cleveland Clinic Foundation Apparatus and method for targeting a body tissue
WO2008049087A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. System for inducing desirable temperature effects on body tissue
WO2008049082A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. Inducing desirable temperature effects on body tissue
EP2954868A1 (en) 2006-10-18 2015-12-16 Vessix Vascular, Inc. Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
US7935144B2 (en) 2006-10-19 2011-05-03 Direct Flow Medical, Inc. Profile reduction of valve implant
US8133213B2 (en) 2006-10-19 2012-03-13 Direct Flow Medical, Inc. Catheter guidance through a calcified aortic valve
EP3075355A1 (en) * 2007-08-23 2016-10-05 Direct Flow Medical, Inc. Translumenally implantable heart valve with formed in place support
US20090076597A1 (en) * 2007-09-19 2009-03-19 Jonathan Micheal Dahlgren System for mechanical adjustment of medical implants
US8906011B2 (en) 2007-11-16 2014-12-09 Kardium Inc. Medical device for use in bodily lumens, for example an atrium
US20090192603A1 (en) * 2008-01-25 2009-07-30 Medtronic, Inc. Adjustable Sizer Devices for Minimally Invasive Cardiac Surgery
US8489172B2 (en) * 2008-01-25 2013-07-16 Kardium Inc. Liposuction system
US20090287304A1 (en) * 2008-05-13 2009-11-19 Kardium Inc. Medical Device for Constricting Tissue or a Bodily Orifice, for example a mitral valve
US8363259B2 (en) * 2008-05-24 2013-01-29 Activiews Ltd. Method for producing printed patches for optical and high-contrast guidance
CA2740867C (en) 2008-10-16 2018-06-12 Aptus Endosystems, Inc. Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
EP2355737B1 (en) 2008-11-17 2021-08-11 Boston Scientific Scimed, Inc. Selective accumulation of energy without knowledge of tissue topography
US20100274227A1 (en) * 2009-02-13 2010-10-28 Alexander Khairkhahan Delivery catheter handle cover
NZ595417A (en) 2009-04-09 2013-10-25 Cardivascular Systems Tissue closure devices, device and systems for delivery, kits and methods therefor
DE102009042465A1 (en) * 2009-09-23 2011-03-31 Fehling Instruments Gmbh & Co. Kg Instrument for the surgical treatment of aortic valve defects
WO2011041571A2 (en) 2009-10-01 2011-04-07 Kardium Inc. Medical device, kit and method for constricting tissue or a bodily orifice, for example, a mitral valve
US8579922B2 (en) * 2009-10-05 2013-11-12 Covidien Lp Method of suture identification and mesh marking for orienting and locating a mesh during hernia repair
EP2493417B1 (en) 2009-10-26 2017-06-21 Cardiokinetix, Inc. Ventricular volume reduction
WO2011083460A2 (en) * 2010-01-11 2011-07-14 Assis Medical Ltd. Device system and method for reshaping tissue openings
JP2013523318A (en) 2010-04-09 2013-06-17 べシックス・バスキュラー・インコーポレイテッド Power generation and control equipment for tissue treatment
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US9050066B2 (en) 2010-06-07 2015-06-09 Kardium Inc. Closing openings in anatomical tissue
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US8940002B2 (en) 2010-09-30 2015-01-27 Kardium Inc. Tissue anchor system
US8870966B2 (en) 2010-10-18 2014-10-28 Apollo Endosurgery, Inc. Intragastric balloon for treating obesity
ES2565348T3 (en) 2010-10-18 2016-04-04 Apollo Endosurgery, Inc. Intragastric implant reagent devices
US9463107B2 (en) 2010-10-18 2016-10-11 Apollo Endosurgery, Inc. Variable size intragastric implant devices
WO2012054514A2 (en) 2010-10-18 2012-04-26 Allergan, Inc. Intragastric implants with duodenal anchors
ES2593753T3 (en) 2010-10-19 2016-12-13 Apollo Endosurgery, Inc. Duodenal sleeve with anchor without perforation
US9498365B2 (en) 2010-10-19 2016-11-22 Apollo Endosurgery, Inc. Intragastric implants with multiple fluid chambers
US9398969B2 (en) 2010-10-19 2016-07-26 Apollo Endosurgery, Inc. Upper stomach gastric implants
US8920447B2 (en) 2010-10-19 2014-12-30 Apollo Endosurgery, Inc. Articulated gastric implant clip
US9198790B2 (en) * 2010-10-19 2015-12-01 Apollo Endosurgery, Inc. Upper stomach gastric implants
US8864840B2 (en) 2010-10-19 2014-10-21 Apollo Endosurgery, Inc. Intragastric implants with collapsible frames
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
FR2968537B1 (en) * 2010-12-09 2013-04-19 Sofradim Production PROTHESIS WITH SEWING IN ZIG-ZAG
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
WO2012100095A1 (en) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
CA2764494A1 (en) 2011-01-21 2012-07-21 Kardium Inc. Enhanced medical device for use in bodily cavities, for example an atrium
US9452016B2 (en) 2011-01-21 2016-09-27 Kardium Inc. Catheter system
US11259867B2 (en) 2011-01-21 2022-03-01 Kardium Inc. High-density electrode-based medical device system
US9480525B2 (en) 2011-01-21 2016-11-01 Kardium, Inc. High-density electrode-based medical device system
US9072511B2 (en) 2011-03-25 2015-07-07 Kardium Inc. Medical kit for constricting tissue or a bodily orifice, for example, a mitral valve
KR20130131471A (en) 2011-04-08 2013-12-03 코비디엔 엘피 Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
EP2701623B1 (en) 2011-04-25 2016-08-17 Medtronic Ardian Luxembourg S.à.r.l. Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
CN103813829B (en) 2011-07-22 2016-05-18 波士顿科学西美德公司 There is the neuromodulation system of the neuromodulation element that can be positioned in spiral guiding piece
US8888692B1 (en) 2011-08-26 2014-11-18 Applied Medical Resources Corporation Trocar cannula assembly and method of manufacture
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
WO2013059202A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US11872135B2 (en) 2012-10-12 2024-01-16 Nikola Dobrilovic, LLC Heart valve sizing ring for valve-sparing aortic root remodeling procedures
US10182913B2 (en) 2012-10-12 2019-01-22 Nikola Dobrilovic Heart valve sizing ring for valve-sparing aortic root remodeling procedures
US9889009B2 (en) 2011-10-26 2018-02-13 Nikola Dobrilovic Heart valve sizing ring and method
EP3366250A1 (en) 2011-11-08 2018-08-29 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
JP6130397B2 (en) 2011-12-23 2017-05-17 べシックス・バスキュラー・インコーポレイテッド Device for remodeling tissue in or adjacent to a body passage
WO2013101452A1 (en) 2011-12-28 2013-07-04 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
USD777926S1 (en) 2012-01-20 2017-01-31 Kardium Inc. Intra-cardiac procedure device
USD777925S1 (en) 2012-01-20 2017-01-31 Kardium Inc. Intra-cardiac procedure device
US8960013B2 (en) * 2012-03-01 2015-02-24 Halliburton Energy Services, Inc. Cement testing
US9763783B2 (en) 2012-04-27 2017-09-19 Nikola Dobrilovic Prosthetic device for heart valve reinforcement and remodeling procedures
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US9198592B2 (en) 2012-05-21 2015-12-01 Kardium Inc. Systems and methods for activating transducers
US9693832B2 (en) 2012-05-21 2017-07-04 Kardium Inc. Systems and methods for selecting, activating, or selecting and activating transducers
US10827977B2 (en) 2012-05-21 2020-11-10 Kardium Inc. Systems and methods for activating transducers
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
WO2014043687A2 (en) 2012-09-17 2014-03-20 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
WO2014047454A2 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10512482B2 (en) 2012-10-05 2019-12-24 Board Of Regents Of The University Of Texas System System and method for scoring the left ventricular endocardium to increase left ventricular compliance
EP2906135A2 (en) 2012-10-10 2015-08-19 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
EP2908744B1 (en) 2012-10-22 2018-08-22 The Cleveland Clinic Foundation Apparatus for targeting a body tissue
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014163987A1 (en) 2013-03-11 2014-10-09 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
WO2014149690A2 (en) 2013-03-15 2014-09-25 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
JP6220044B2 (en) 2013-03-15 2017-10-25 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Medical device for renal nerve ablation
JP6294455B2 (en) 2013-03-15 2018-03-14 アプライド メディカル リソーシーズ コーポレイション Trocar cannula assembly having low profile insertion configuration and manufacturing method
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
CN105473091B (en) 2013-06-21 2020-01-21 波士顿科学国际有限公司 Renal denervation balloon catheter with co-movable electrode supports
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
WO2015002787A1 (en) 2013-07-01 2015-01-08 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
WO2015006573A1 (en) 2013-07-11 2015-01-15 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
CN105392435B (en) 2013-07-22 2018-11-09 波士顿科学国际有限公司 Renal nerve ablation catheter with twisting sacculus
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
EP4049605A1 (en) 2013-08-22 2022-08-31 Boston Scientific Scimed Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
WO2015031476A1 (en) 2013-08-27 2015-03-05 Board Of Regents, The University Of Texas System System and method for cutting trabeculae carneae of the left ventricle to increase lv compliance
WO2015035047A1 (en) 2013-09-04 2015-03-12 Boston Scientific Scimed, Inc. Radio frequency (rf) balloon catheter having flushing and cooling capability
EP3043733A1 (en) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
WO2015057584A1 (en) 2013-10-15 2015-04-23 Boston Scientific Scimed, Inc. Medical device balloon
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
EP3060153A1 (en) 2013-10-25 2016-08-31 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
CN105899157B (en) 2014-01-06 2019-08-09 波士顿科学国际有限公司 Tear-proof flexible circuit assembly
DK3096711T3 (en) * 2014-01-26 2021-05-25 Butterfly Medical Ltd DILATION DEVICE FOR PROSTATIC URINE PIPE
US11027106B2 (en) 2014-01-26 2021-06-08 Butterfly Medical Ltd. Dilating device and method for prostatic urethra
EP3102136B1 (en) 2014-02-04 2018-06-27 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US10709490B2 (en) 2014-05-07 2020-07-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods
BR112017006248A2 (en) 2014-09-28 2017-12-12 Cardiokinetix Inc heart failure treatment apparatus
US10368936B2 (en) 2014-11-17 2019-08-06 Kardium Inc. Systems and methods for selecting, activating, or selecting and activating transducers
US10722184B2 (en) 2014-11-17 2020-07-28 Kardium Inc. Systems and methods for selecting, activating, or selecting and activating transducers
CN104720861B (en) * 2015-03-03 2017-09-22 上海形状记忆合金材料有限公司 Weave class capacity-reduction device
FI3328317T3 (en) * 2015-07-29 2023-01-13 Retracting or/and supporting periurethral tissue
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
US11504265B2 (en) 2020-06-18 2022-11-22 Medline Industries, Lp Urine collection device, system, and method

Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568659A (en) * 1968-09-24 1971-03-09 James N Karnegis Disposable percutaneous intracardiac pump and method of pumping blood
US4685446A (en) * 1984-02-21 1987-08-11 Choy Daniel S J Method for using a ventricular assist device
US4771765A (en) * 1984-02-21 1988-09-20 Choy Daniel S J Heart assist device and method of use
US4785795A (en) * 1985-07-15 1988-11-22 Abiomed Cardiovascular, Inc. High-frequency intra-arterial cardiac support system
US4817637A (en) * 1987-11-25 1989-04-04 Medical Engineering Corporation Subcutaneous injection and withdrawal site
US4861330A (en) * 1987-03-12 1989-08-29 Gene Voss Cardiac assist device and method
US4902273A (en) * 1984-02-21 1990-02-20 Choy Daniel S J Heart assist device
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US5139517A (en) * 1989-11-08 1992-08-18 Corral David F Orthotopic intraventricular heart pump
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5171299A (en) * 1991-08-02 1992-12-15 Baxter International Inc. Balloon catheter inflation pressure and diameter display apparatus and method
US5176619A (en) * 1989-05-05 1993-01-05 Jacob Segalowitz Heart-assist balloon pump with segmented ventricular balloon
US5489296A (en) * 1993-12-17 1996-02-06 Autogenics Heart valve measurement tool
US5509428A (en) * 1994-05-31 1996-04-23 Dunlop; Richard W. Method and apparatus for the creation of tricuspid regurgitation
US5603337A (en) * 1994-12-05 1997-02-18 Jarvik; Robert Two-stage cardiomyoplasty
US5632776A (en) * 1990-11-22 1997-05-27 Toray Industries, Inc. Implantation materials
US5725552A (en) * 1994-07-08 1998-03-10 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US5738626A (en) * 1996-06-14 1998-04-14 Jarvik; Robert Two-step cardiomyoplasty with ventricular reduction
US5749839A (en) * 1994-08-18 1998-05-12 Duke University Direct mechanical bi-ventricular cardiac assist device
US5814098A (en) * 1995-06-07 1998-09-29 St. Jude Medical, Inc. Adjustable sizing apparatus
US5843177A (en) * 1996-05-02 1998-12-01 St. Jude Medical, Inc. Apparatus for attaching a handle to an annuloplasty ring implantation device
US5846261A (en) * 1994-07-08 1998-12-08 Aga Medical Corp. Percutaneous catheter directed occlusion devices
US5868779A (en) * 1997-08-15 1999-02-09 Ruiz; Carlos E. Apparatus and methods for dilating vessels and hollow-body organs
US5885228A (en) * 1996-05-08 1999-03-23 Heartport, Inc. Valve sizer and method of use
US5904680A (en) * 1992-09-25 1999-05-18 Ep Technologies, Inc. Multiple electrode support structures having optimal bio-mechanical characteristics
US5921935A (en) * 1989-09-18 1999-07-13 The Research Foundation Of State University Of New York Method and apparatus utilizing heart sounds for determining pressures associated with the left atrium
US5944738A (en) * 1998-02-06 1999-08-31 Aga Medical Corporation Percutaneous catheter directed constricting occlusion device
US5951543A (en) * 1997-06-30 1999-09-14 Clinicon Corporation Delivery system and method for surgical laser
US5957977A (en) * 1996-01-02 1999-09-28 University Of Cincinnati Activation device for the natural heart including internal and external support structures
US5964806A (en) * 1997-06-12 1999-10-12 Uromedica, Inc. Adjustable implantable genitourinary device
US5971911A (en) * 1993-06-17 1999-10-26 Wilk; Peter J. Intrapericardial assist device and associated method
US6004329A (en) * 1997-05-29 1999-12-21 Baxter International Inc. Shape-adjustable surgical implement handle
US6019739A (en) * 1998-06-18 2000-02-01 Baxter International Inc. Minimally invasive valve annulus sizer
US6024096A (en) * 1998-05-01 2000-02-15 Correstore Inc Anterior segment ventricular restoration apparatus and method
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US6123715A (en) * 1994-07-08 2000-09-26 Amplatz; Curtis Method of forming medical devices; intravascular occlusion devices
US6125852A (en) * 1993-02-22 2000-10-03 Heartport, Inc. Minimally-invasive devices and methods for treatment of congestive heart failure
US6143012A (en) * 1997-05-06 2000-11-07 Orthofix S.R.L. Intramedullary awl assembly for preparation for a femoral-style nailing
US6152144A (en) * 1998-11-06 2000-11-28 Appriva Medical, Inc. Method and device for left atrial appendage occlusion
US6162168A (en) * 1997-01-02 2000-12-19 Myocor, Inc. Heart wall tension reduction apparatus
US6179971B1 (en) * 1999-04-30 2001-01-30 Kse, Inc. Two stage process and catalyst for photocatalytic conversion of contaminants
US6183411B1 (en) * 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US6221104B1 (en) * 1998-05-01 2001-04-24 Cor Restore, Inc. Anterior and interior segment cardiac restoration apparatus and method
US6231601B1 (en) * 1997-05-29 2001-05-15 Edwards Lifesciences Corporation Method of surgery including adjusting the shape of an implement handle
US6261832B1 (en) * 1994-12-13 2001-07-17 Peter K. Law Automated cell processor
US6350281B1 (en) * 1999-09-14 2002-02-26 Edwards Lifesciences Corp. Methods and apparatus for measuring valve annuluses during heart valve-replacement surgery
US6360749B1 (en) * 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US6406420B1 (en) * 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6419669B1 (en) * 1999-09-20 2002-07-16 Appriva Medical, Inc. Method and apparatus for patching a tissue opening
US6544167B2 (en) * 1998-05-01 2003-04-08 Correstore, Inc. Ventricular restoration patch
US6551303B1 (en) * 1999-10-27 2003-04-22 Atritech, Inc. Barrier device for ostium of left atrial appendage
US6652556B1 (en) * 1999-10-27 2003-11-25 Atritech, Inc. Filter apparatus for ostium of left atrial appendage
US6681773B2 (en) * 2001-02-28 2004-01-27 Chase Medical, Inc. Kit and method for use during ventricular restoration
US6852076B2 (en) * 1999-08-09 2005-02-08 Cardiokinetix, Inc. Method for improving cardiac function

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2701559A (en) 1951-08-02 1955-02-08 William A Cooper Apparatus for exfoliating and collecting diagnostic material from inner walls of hollow viscera
US3874388A (en) 1973-02-12 1975-04-01 Ochsner Med Found Alton Shunt defect closure system
US3983883A (en) * 1975-04-10 1976-10-05 Massey-Ferguson Industries Limited Grain saving apparatus
US3983863A (en) 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
US4690134A (en) 1985-07-01 1987-09-01 Snyders Robert V Ventricular assist device
US4938231A (en) 1985-10-22 1990-07-03 Telectronics N.V. Defibrillator electrode
SE454942B (en) 1986-05-22 1988-06-13 Astra Tech Ab HEART HELP DEVICE FOR INOPERATION IN BROSTHALAN
US4821723A (en) 1987-02-27 1989-04-18 Intermedics Inc. Biphasic waveforms for defibrillation
US4917089A (en) 1988-08-29 1990-04-17 Sideris Eleftherios B Buttoned device for the transvenous occlusion of intracardiac defects
US5411527A (en) 1989-05-03 1995-05-02 Intermedics, Inc. Difibrillation electrodes and implantation
US5041130A (en) 1989-07-31 1991-08-20 Baxter International Inc. Flexible annuloplasty ring and holder
US4973300A (en) 1989-09-22 1990-11-27 Pioneering Technologies, Inc. Cardiac sling for circumflex coronary artery surgery
US5131905A (en) 1990-07-16 1992-07-21 Grooters Ronald K External cardiac assist device
ES2020787A6 (en) 1990-07-20 1991-09-16 Figuera Aymerich Diego Intra-ventricular expansible assist pump
JP2555298B2 (en) 1990-11-10 1996-11-20 テルモ株式会社 CATHETER BALLOON, CATHETER BALLOON MANUFACTURING METHOD, AND BALLOON CATHETER
US5465717A (en) * 1991-02-15 1995-11-14 Cardiac Pathways Corporation Apparatus and Method for ventricular mapping and ablation
US5255678A (en) 1991-06-21 1993-10-26 Ecole Polytechnique Mapping electrode balloon
EP0545091B1 (en) 1991-11-05 1999-07-07 The Children's Medical Center Corporation Occluder for repair of cardiac and vascular defects
EP0541063B1 (en) 1991-11-05 1998-09-02 The Children's Medical Center Corporation Improved occluder for repair of cardiac and vascular defects
US5258000A (en) 1991-11-25 1993-11-02 Cook Incorporated Tissue aperture repair device
US5192314A (en) 1991-12-12 1993-03-09 Daskalakis Michael K Synthetic intraventricular implants and method of inserting
US5797960A (en) 1993-02-22 1998-08-25 Stevens; John H. Method and apparatus for thoracoscopic intracardiac procedures
US20020029783A1 (en) 1993-02-22 2002-03-14 Stevens John H. Minimally-invasive devices and methods for treatment of congestive heart failure
US5409000A (en) * 1993-09-14 1995-04-25 Cardiac Pathways Corporation Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method
US5526810A (en) 1993-10-07 1996-06-18 Wang; Dai-Yuen Intraventricular mapping catheter
JP3185906B2 (en) 1993-11-26 2001-07-11 ニプロ株式会社 Prosthesis for atrial septal defect
US6216043B1 (en) 1994-03-04 2001-04-10 Ep Technologies, Inc. Asymmetric multiple electrode support structures
US5433727A (en) 1994-08-16 1995-07-18 Sideris; Eleftherios B. Centering buttoned device for the occlusion of large defects for occluding
US5722401A (en) 1994-10-19 1998-03-03 Cardiac Pathways Corporation Endocardial mapping and/or ablation catheter probe
US5609157A (en) 1995-02-17 1997-03-11 Ep Technologies, Inc. Systems and methods for analyzing biopotential morphologies in body tissue using iterative techniques
US5800528A (en) 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
AU7671696A (en) 1996-01-18 1997-08-11 University Of New Mexico Soft actuators and artificial muscles
US5736626A (en) 1996-01-29 1998-04-07 The Perkin-Elmer Corporation Solid support reagents for the direct synthesis of 3'-labeled polynucleotides
US6368356B1 (en) 1996-07-11 2002-04-09 Scimed Life Systems, Inc. Medical devices comprising hydrogel polymers having improved mechanical properties
US5923770A (en) 1996-09-30 1999-07-13 Siemens Corporate Research, Inc. 3D cardiac motion recovery system using tagged MR images
US5702343A (en) 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
US5908445A (en) 1996-10-28 1999-06-01 Ep Technologies, Inc. Systems for visualizing interior tissue regions including an actuator to move imaging element
US6162537A (en) 1996-11-12 2000-12-19 Solutia Inc. Implantable fibers and medical articles
US6205411B1 (en) 1997-02-21 2001-03-20 Carnegie Mellon University Computer-assisted surgery planner and intra-operative guidance system
US5846260A (en) 1997-05-08 1998-12-08 Embol-X, Inc. Cannula with a modular filter for filtering embolic material
DE69908526T2 (en) 1998-04-03 2004-05-06 Koninklijke Philips Electronics N.V. Image processing method and system using contour detection steps
US6210338B1 (en) * 1998-08-21 2001-04-03 Aga Medical Corp. Sizing catheter for measuring cardiovascular structures
US6685627B2 (en) 1998-10-09 2004-02-03 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US7887477B2 (en) 1999-08-09 2011-02-15 Cardiokinetix, Inc. Method of improving cardiac function using a porous membrane
US6322588B1 (en) 1999-08-17 2001-11-27 St. Jude Medical, Inc. Medical devices with metal/polymer composites
US6179791B1 (en) * 1999-09-21 2001-01-30 Acorn Cardiovascular, Inc. Device for heart measurement
ITPC20000013A1 (en) 2000-04-13 2000-07-13 Paolo Ferrazzi INTROVENTRICULAR DEVICE AND RELATED METHOD FOR THE TREATMENT AND CORRECTION OF MYOCARDIOPATHIES.
US6887192B1 (en) 2000-09-08 2005-05-03 Converge Medical, Inc. Heart support to prevent ventricular remodeling
US20030181940A1 (en) 2001-02-28 2003-09-25 Gregory Murphy Ventricular restoration shaping apparatus and method of use
US20020133227A1 (en) 2001-02-28 2002-09-19 Gregory Murphy Ventricular restoration patch apparatus and method of use
US6726696B1 (en) 2001-04-24 2004-04-27 Advanced Catheter Engineering, Inc. Patches and collars for medical applications and methods of use
US7485088B2 (en) * 2001-09-05 2009-02-03 Chase Medical L.P. Method and device for percutaneous surgical ventricular repair
US6685620B2 (en) 2001-09-25 2004-02-03 The Foundry Inc. Ventricular infarct assist device and methods for using it

Patent Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568659A (en) * 1968-09-24 1971-03-09 James N Karnegis Disposable percutaneous intracardiac pump and method of pumping blood
US4685446A (en) * 1984-02-21 1987-08-11 Choy Daniel S J Method for using a ventricular assist device
US4771765A (en) * 1984-02-21 1988-09-20 Choy Daniel S J Heart assist device and method of use
US4902273A (en) * 1984-02-21 1990-02-20 Choy Daniel S J Heart assist device
US4785795A (en) * 1985-07-15 1988-11-22 Abiomed Cardiovascular, Inc. High-frequency intra-arterial cardiac support system
US4861330A (en) * 1987-03-12 1989-08-29 Gene Voss Cardiac assist device and method
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US4817637A (en) * 1987-11-25 1989-04-04 Medical Engineering Corporation Subcutaneous injection and withdrawal site
US5176619A (en) * 1989-05-05 1993-01-05 Jacob Segalowitz Heart-assist balloon pump with segmented ventricular balloon
US5921935A (en) * 1989-09-18 1999-07-13 The Research Foundation Of State University Of New York Method and apparatus utilizing heart sounds for determining pressures associated with the left atrium
US5139517A (en) * 1989-11-08 1992-08-18 Corral David F Orthotopic intraventricular heart pump
US5632776A (en) * 1990-11-22 1997-05-27 Toray Industries, Inc. Implantation materials
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5171299A (en) * 1991-08-02 1992-12-15 Baxter International Inc. Balloon catheter inflation pressure and diameter display apparatus and method
US5904680A (en) * 1992-09-25 1999-05-18 Ep Technologies, Inc. Multiple electrode support structures having optimal bio-mechanical characteristics
US6125852A (en) * 1993-02-22 2000-10-03 Heartport, Inc. Minimally-invasive devices and methods for treatment of congestive heart failure
US5971911A (en) * 1993-06-17 1999-10-26 Wilk; Peter J. Intrapericardial assist device and associated method
US5489296A (en) * 1993-12-17 1996-02-06 Autogenics Heart valve measurement tool
US5509428A (en) * 1994-05-31 1996-04-23 Dunlop; Richard W. Method and apparatus for the creation of tricuspid regurgitation
US6123715A (en) * 1994-07-08 2000-09-26 Amplatz; Curtis Method of forming medical devices; intravascular occlusion devices
US5725552A (en) * 1994-07-08 1998-03-10 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US5846261A (en) * 1994-07-08 1998-12-08 Aga Medical Corp. Percutaneous catheter directed occlusion devices
US5749839A (en) * 1994-08-18 1998-05-12 Duke University Direct mechanical bi-ventricular cardiac assist device
US5603337A (en) * 1994-12-05 1997-02-18 Jarvik; Robert Two-stage cardiomyoplasty
US6261832B1 (en) * 1994-12-13 2001-07-17 Peter K. Law Automated cell processor
US5814098A (en) * 1995-06-07 1998-09-29 St. Jude Medical, Inc. Adjustable sizing apparatus
US5957977A (en) * 1996-01-02 1999-09-28 University Of Cincinnati Activation device for the natural heart including internal and external support structures
US5843177A (en) * 1996-05-02 1998-12-01 St. Jude Medical, Inc. Apparatus for attaching a handle to an annuloplasty ring implantation device
US5885228A (en) * 1996-05-08 1999-03-23 Heartport, Inc. Valve sizer and method of use
US5738626A (en) * 1996-06-14 1998-04-14 Jarvik; Robert Two-step cardiomyoplasty with ventricular reduction
US6162168A (en) * 1997-01-02 2000-12-19 Myocor, Inc. Heart wall tension reduction apparatus
US6406420B1 (en) * 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6143012A (en) * 1997-05-06 2000-11-07 Orthofix S.R.L. Intramedullary awl assembly for preparation for a femoral-style nailing
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US6231601B1 (en) * 1997-05-29 2001-05-15 Edwards Lifesciences Corporation Method of surgery including adjusting the shape of an implement handle
US6004329A (en) * 1997-05-29 1999-12-21 Baxter International Inc. Shape-adjustable surgical implement handle
US5964806A (en) * 1997-06-12 1999-10-12 Uromedica, Inc. Adjustable implantable genitourinary device
US5951543A (en) * 1997-06-30 1999-09-14 Clinicon Corporation Delivery system and method for surgical laser
US5868779A (en) * 1997-08-15 1999-02-09 Ruiz; Carlos E. Apparatus and methods for dilating vessels and hollow-body organs
US5944738A (en) * 1998-02-06 1999-08-31 Aga Medical Corporation Percutaneous catheter directed constricting occlusion device
US6221104B1 (en) * 1998-05-01 2001-04-24 Cor Restore, Inc. Anterior and interior segment cardiac restoration apparatus and method
US6544167B2 (en) * 1998-05-01 2003-04-08 Correstore, Inc. Ventricular restoration patch
US6024096A (en) * 1998-05-01 2000-02-15 Correstore Inc Anterior segment ventricular restoration apparatus and method
US6019739A (en) * 1998-06-18 2000-02-01 Baxter International Inc. Minimally invasive valve annulus sizer
US6183411B1 (en) * 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US6360749B1 (en) * 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US6152144A (en) * 1998-11-06 2000-11-28 Appriva Medical, Inc. Method and device for left atrial appendage occlusion
US6179971B1 (en) * 1999-04-30 2001-01-30 Kse, Inc. Two stage process and catalyst for photocatalytic conversion of contaminants
US6852076B2 (en) * 1999-08-09 2005-02-08 Cardiokinetix, Inc. Method for improving cardiac function
US6350281B1 (en) * 1999-09-14 2002-02-26 Edwards Lifesciences Corp. Methods and apparatus for measuring valve annuluses during heart valve-replacement surgery
US6419669B1 (en) * 1999-09-20 2002-07-16 Appriva Medical, Inc. Method and apparatus for patching a tissue opening
US6551303B1 (en) * 1999-10-27 2003-04-22 Atritech, Inc. Barrier device for ostium of left atrial appendage
US6652556B1 (en) * 1999-10-27 2003-11-25 Atritech, Inc. Filter apparatus for ostium of left atrial appendage
US6681773B2 (en) * 2001-02-28 2004-01-27 Chase Medical, Inc. Kit and method for use during ventricular restoration
US6702763B2 (en) * 2001-02-28 2004-03-09 Chase Medical, L.P. Sizing apparatus and method for use during ventricular restoration
US6959711B2 (en) * 2001-02-28 2005-11-01 Chase Medical, L.P. Kit and method for use during ventricular restoration
US6994093B2 (en) * 2001-02-28 2006-02-07 Chase Medical, L.P. Ventricular restoration shaping apparatus and method of use

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
US8267852B2 (en) 1997-01-02 2012-09-18 Edwards Lifesciences, Llc Heart wall tension reduction apparatus and method
US8460173B2 (en) 1997-01-02 2013-06-11 Edwards Lifesciences, Llc Heart wall tension reduction apparatus and method
US7678145B2 (en) 2002-01-09 2010-03-16 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US8070805B2 (en) 2002-01-09 2011-12-06 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US8506624B2 (en) 2002-01-09 2013-08-13 Edwards Lifesciences, Llc Devices and methods for heart valve treatment
US7666224B2 (en) 2002-11-12 2010-02-23 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US20060247672A1 (en) * 2005-04-27 2006-11-02 Vidlund Robert M Devices and methods for pericardial access
CN103340663A (en) * 2013-06-17 2013-10-09 李宝童 Capsule type coronary oppressing device and method for manufacturing chronic myocardial ischemia animal model
WO2017083133A1 (en) * 2015-11-12 2017-05-18 Sonacare Medical Llc Tissue stabilization for therapeutic ultrasound
US9974983B2 (en) 2015-11-12 2018-05-22 SonaCare Medical, LLC Tissue stabilization for therapeutic ultrasound

Also Published As

Publication number Publication date
US20020133054A1 (en) 2002-09-19
US20050278024A1 (en) 2005-12-15
US20020133182A1 (en) 2002-09-19
US20030192561A1 (en) 2003-10-16
US6959711B2 (en) 2005-11-01
US20020133143A1 (en) 2002-09-19
US20030050659A1 (en) 2003-03-13
US20030045896A1 (en) 2003-03-06
US6681773B2 (en) 2004-01-27
US6994093B2 (en) 2006-02-07
US6702763B2 (en) 2004-03-09

Similar Documents

Publication Publication Date Title
US6994093B2 (en) Ventricular restoration shaping apparatus and method of use
US20020133227A1 (en) Ventricular restoration patch apparatus and method of use
US6024096A (en) Anterior segment ventricular restoration apparatus and method
US6450171B1 (en) Anterior and inferior segment ventricular restoration apparatus and method
US7485088B2 (en) Method and device for percutaneous surgical ventricular repair
US20040243170A1 (en) Method and device for percutaneous surgical ventricular repair
JP4964235B2 (en) Perimeter seal for ventricular compartment device
EP1638627B1 (en) Device for proactive modulation of cardiac strain patterns
EP1862128B1 (en) Devices for heart valve treatment
AU2002259297B2 (en) Apparatus, kit, and method for use during ventricular restoration
WO2007001482A1 (en) Method and device for surgical ventricular repair
AU2002259297A1 (en) Apparatus, kit, and method for use during ventricular restoration
US20030181940A1 (en) Ventricular restoration shaping apparatus and method of use
CA2473929A1 (en) An apical patch and method of use
CA2558017A1 (en) Method and device for percutaneous surgical ventricular repair
AU2003207651A1 (en) An apical patch and method of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: CMI HOLDING COMPANY, INC, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHASE MEDICAL, LP;REEL/FRAME:019858/0817

Effective date: 20070921

AS Assignment

Owner name: CAPITAL SOUTHWEST CORPORATION, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CMI HOLDING COMPANY, INC.;REEL/FRAME:020462/0048

Effective date: 20080118

AS Assignment

Owner name: CAPITAL SOUTHWEST CORPORATION, TEXAS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RE-RECORD THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 020462 FRAME 0048. ASSIGNOR(S) HEREBY CONFIRMS THE FROM ASSIGNMENT TO SECURITY AGREEMENT.;ASSIGNOR:CMI HOLDING COMPANY, INC.;REEL/FRAME:020487/0438

Effective date: 20080118

Owner name: CAPITAL SOUTHWEST CORPORATION, TEXAS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RE-RECORD THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 020462 FRAME 0048. ASSIGNOR(S) HEREBY CONFIRMS THE FROM ASSIGNMENT TO SECURITY AGREEMENT;ASSIGNOR:CMI HOLDING COMPANY, INC.;REEL/FRAME:020487/0438

Effective date: 20080118

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MEYERTONS, HOOD, KIVLIN, KOWERT & GOETZEL, P.C., T

Free format text: SECURITY AGREEMENT;ASSIGNOR:CHASE MEDICAL, LP;REEL/FRAME:021076/0637

Effective date: 20070530

AS Assignment

Owner name: CAPITAL SOUTHWEST CORPORATION,TEXAS

Free format text: SECURITY AGREEMENT;ASSIGNOR:CMI HOLDING COMPANY, INC.;REEL/FRAME:024091/0248

Effective date: 20100312

Owner name: CAPITAL SOUTHWEST CORPORATION, TEXAS

Free format text: SECURITY AGREEMENT;ASSIGNOR:CMI HOLDING COMPANY, INC.;REEL/FRAME:024091/0248

Effective date: 20100312

AS Assignment

Owner name: CHASE MEDICAL, LP, TEXAS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MEYERTONS, HOOD, KIVLIN, KOWERT & GOETZEL, P.C.;REEL/FRAME:025709/0087

Effective date: 20110107